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THE EFFECT OF SURGICAL WEIGHT LOSS INTERVENTIONS ON 
VASCULAR ENDOTHELIAL DYSFUNCTION 
ALYSSA DOBYNS 
ABSTRACT 
Background and Aims: Obesity is associated with vascular endothelial 
dysfunction, which predisposes obese persons to cardiovascular disease. Fat 
loss in obese persons can lead to metabolic improvements that promote 
improved cardiovascular health and decrease risk of stroke or myocardial 
infarction.  The objective of this study was to assess the potential of weight loss 
achieved by bariatric surgery to improve endothelial function.  
Methods: Patients scheduled to undergo bariatric surgery were prospectively 
followed. Biochemical analyses and vascular function testing were performed 
preoperatively and again at 1, 3, 6, and 12 months postoperatively. FMD and 
NMD were measured to assess macrovascular endothelial function and ∆ 
hyperemic flow was measured to assess microvascular endothelial function.  
Results: Patients (n = 375) ages 41.76 ± 12.35 years, with baseline BMI of 45.64 
± 8.36, experienced a weight reduction of 82.07 ± 33.98 lbs the year following 
surgery. FMD % increased by 1.28 ± 5.49, NMD % by 4.26 ± 6.23, and ∆ 
hyperemic flow % by 262.1 ± 519.97. All vascular function variables 
demonstrated a significant increase over time (p < 0.05) with ∆ hyperemic flow % 
experiencing the most significant change (p < 0.0001). No difference was found 
  vi 
in improvement in vascular function between high (>13 µIU/ml) and low (≤13 
µIU/ml) baseline plasma insulin groups (p values all > 0.05). 
Conclusions: Bariatric surgery was associated with an improvement in 
macrovascular and microvascular endothelial function. Further analyses is 
needed to determine which clinical parameters are optimal predictors of 
improvements in vascular endothelial function after bariatric surgery.  
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 1 
INTRODUCTION 
 
 Obesity continues to be a global public health concern, especially in the 
United States where it remains highest, with up to 36% of adults over the age of 
20 classified as obese (Arroyo-Johnson & Mincey, 2016; Wang, McPherson, 
Marsh, Gortmaker, & Brown, 2011). Obesity can be measured using Body Mass 
Index (BMI) which is calculated by dividing weight, in kg, by height, in meters 
squared (Arroyo-Johnson & Mincey, 2016). The World Health Organization 
classifies persons over 20 years of age with a BMI between 25-29.9 kg/m2 as 
overweight, those with a BMI > 30 kg/m2 as obese, and those with a BMI > 40 
kg/m2 as obese class III, or morbidly obese (Information, Pike, MD, & USA, 
2015). In a 2013-2014 US survey, the prevalence of obesity was shown to be 
35% in men and 40.4% in women, with 5.5% of men and 9.9% of women 
classified as obese class III (Flegal, Kruszon-Moran, Carroll, Fryar, & Ogden, 
2016). A simulation model projected about three out of four people in the US to 
be overweight by the year 2030 if current obesity trends continue, adding 65 
million individuals to the current obese population in the country (Wang et al., 
2011). These projections have significant health and economic consequences, 
due to the statistically significant association of obesity with increased risk of type 
II diabetes, cardiovascular diseases, asthma, osteoarthritis, cancer (with the 
exception of esophageal and prostate cancer),  and gallbladder disease (Guh et 
al., 2009; Wang et al., 2011). The Framingham Heart Study showed obesity to be 
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a significant independent predictor of cardiovascular disease, a risk which is 
notably increased in obese persons with hypertension, dyslipidemia, or 
microalbuminuria (Collaboration, 2009; Hubert, Feinleib, Mcnamara, & Castelli, 
1983; Isomaa et al., 2001).  
 
Endothelial Dysfunction 
 Obesity-related endothelial dysfunction is an important contributor to the 
development of cardiovascular risk-factors, including insulin-resistance and 
hypertension, which predispose obese persons to cardiovascular disease (Serné 
et al., 1999). Atherosclerosis can begin in childhood with deposition of 
cholesterol from LDL in the sub endothelial region of blood vessels and typically 
advance without clinical manifestation throughout early adulthood (D. Celermajer 
et al., 1992a; Ross, 1993, 1999). Early atherosclerotic lesions can mature to 
advanced atherosclerotic plaques with a high state of inflammation without 
luminal narrowing or symptoms, or to structural changes in the arteries causing 
luminal stenosis, which often produce symptoms and can be identified and 
treated before a fatal or debilitating event (D. Celermajer et al., 1992a; Ross, 
1993). Changes in endothelial biology, and hence endothelial function, precede 
the development of atherosclerosis and contribute to progression of the disease 
(Ross, 1993, 1999). 
 As the barrier between the blood and the vessel wall, the vascular 
endothelium is of critical importance in balancing tissue perfusion and 
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consequently oxygen supply to organs, as well as regulating vascular 
remodeling, inflammation, and thrombosis (Deanfield, Halcox, & Rabelink, 2007; 
Schechter & Gladwin, 2003; Widlansky, Gokce, Keaney, & Vita, 2003). It 
performs these functions via the production and release of vasoactive 
substances, in addition to responding to circulating vasoactive molecules 
(Schechter & Gladwin, 2003). Thus, the production of these molecules is crucial 
in regulating vascular tone and maintaining vascular homeostasis (Deanfield et 
al., 2007). 
 Nitric oxide is a vasodilator released from the endothelium in response to 
certain stimuli, primarily laminar shear stress (D. S. Celermajer, 1997). Most NO 
produced by the endothelium is generated via the oxidation of L-arginine to L-
citrulline and NO, by the membrane-bound enzyme endothelial nitric oxide 
synthase (eNOS) (Forstermann & Munzel, 2006). Dimerization of eNOS and the 
cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4) are necessary for the enzyme 
to produce NO (Forstermann & Munzel, 2006). It is activated in response to 
shear stress, often brought about by changes in cardiac output, as well as 
various signaling molecules (e.g. adenosine, serotonin, bradykinin, and vascular 
endothelial growth factor) (Corson et al., 1996; Govers & Rabelink, 2001). Once 
produced by eNOS, NO gas diffuses to the vascular smooth muscle, activating 
guanylate cyclase to produce cGMP, causing vasodilatation (Corson et al., 
1996). It also reduces the activity of various proteins through S-nitrosylation of 
their cysteine residues, inhibiting the production of adhesion molecules, 
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chemokines, and cytokines (Hansson, 2005; Stamler, Lamas, & Fang, 2001). 
Therefore NO protects the cell against atherogenesis by inhibiting vascular 
smooth muscle cell proliferation, leukocyte adhesion, and platelet aggregation 
and adhesion (Forstermann & Munzel, 2006). 
 Endothelial dysfunction occurs when the normal, quiescent phenotype of 
the endothelium is disturbed (Deanfield et al., 2007).  This can occur by many 
mechanisms. Exposure to certain pathogens or the presence of cardiovascular 
risk factors (e.g. hypertension, diabetes mellitus, hypercholesterolemia, or 
chronic smoking) lead to the upregulation of eNOS, as well as NADPH oxidases 
(NOX) (Sorescu et al., 2002). The superoxide produced by NOX reacts with the 
NO produced by eNOS to form peroxynitrite, which can either oxidize BH4 
rendering this essential cofactor to eNOS biologically inactive, or it can damage 
the zinc-thiolate cluster of eNOS, destabilizing the enzyme (Milstien & Katusic, 
1999; Zou, Shi, & Cohen, 2002). This results in eNOS uncoupling and further 
production of reactive oxygen species (Forstermann & Munzel, 2006). Although 
the production of ROS is part of the normal host defense, the extent and duration 
of endothelial activation is what differentiates a normal host defense from 
endothelial dysfunction. Chronic ROS production exceeds the capacity of 
protective anti-oxidants in the endothelial cell resulting in a sustained endothelial 
activation (Deanfield et al., 2007).  Excessive ROS cause additional oxidative 
damage and in the presence of superoxide dismutase form hydrogen peroxide 
(Rhee, 2006). Hydrogen peroxide interacts with the cysteine residues of proteins, 
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amplifying their activity and resulting in a response which is in sharp contrast to 
the response generated by NO (Giannoni, Buricchi, Raugei, Ramponi, & 
Chiarugi, 2005). Production of adhesion molecules, cytokines, and chemokines 
rise, increasing the likelihood of development of morphological atherosclerotic 
changes (Ross, 1999). NO is therefore an endogenous anti-atherogenic 
substance and the assessment of its bioavailability is key in evaluating the 
pathogenesis of atherosclerosis. 
  
Clinical Assessment of Endothelial Function 
Determination of the bioavailability of endothelium-derived NO can be 
made by evaluating the extent of vasodilation after stimulating the release of NO 
from the endothelium using pharmacological or physiological agents (Ludmer et 
al., 1986; Okumura et al., 1992). The vasodilation of blood vessels in response to 
shear stress, resulting from an increase in flow, is known as flow mediated 
dilatation, or FMD (Raitakari & Celermajer, 2000). Original endothelial function 
studies were invasive, requiring coronary angiography, arterial cannulation, or 
intra-arterial pharmacologic stimulation, limiting their use to only those patients 
with more advanced cardiovascular disease and making repeated studies 
impractical (Corretti et al., 2002; Cox et al., 1989; Raitakari & Celermajer, 2000). 
In 1992, a noninvasive method of evaluating endothelial function was developed, 
using high-resolution ultrasound to assess FMD (D. Celermajer et al., 1992b). 
FMD impairment in the systemic arteries, which can be assessed by evaluation 
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of FMD in the brachial artery, correlates with the angiographic degree of coronary 
artery disease (T. Anderson et al., 1995). Therefore, ultrasound analysis of the 
brachial artery can be used as an alternative to direct evaluation of the coronary 
arteries, to assess the extent of CAD (Neunteufl et al., 1997). 
Ultrasound assessment of FMD involves the occlusion of blood flow using 
a sphygmomanometer cuff (Deanfield et al., 2007).  Measurements of arterial 
diameter and blood velocity are taken prior to vessel occlusion. The cuff is then 
inflated for 5 minutes to ≥ 25 to 50 mmHg suprasystolic pressure, in order to 
occlude the vessel (Harris, Nishiyama, Wray, & Richardson, 2010). Occlusion 
allows for ischemia of the distal tissues, which upon cuff deflation elicits a 
reactive hyperemic response (D. Celermajer et al., 1992b). Reactive hyperemia 
increases the laminar shear stress forces at a vector parallel to the long axis of 
the brachial artery, stimulating mechanoreceptors on the luminal membrane of 
the endothelial cell (Niebauer & Cooke, 1996). Stimulation of mechanoreceptors 
upregulates the expression of Phosphokinase A, which in turn increases the 
activity of eNOS and therefore the production of NO (Sessa, 2004). NO-induced 
increase in arterial diameter can be measured from the ultrasound images and 
expressed as a percentage of the previously measured pre-occlusion diameter to 
give % FMD (Harris et al., 2010).  
(1)  𝐹𝑀𝐷 (%) =
(𝑝𝑒𝑎𝑘 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟) − (𝑝𝑟𝑒 − 𝑜𝑐𝑐𝑙𝑢𝑠𝑖𝑜𝑛 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)
(𝑝𝑟𝑒 − 𝑜𝑐𝑐𝑙𝑢𝑠𝑖𝑜𝑛 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)
 × 100 
FMD is primarily a result of local endothelial release of NO (Corretti et al., 
2002). In contrast, nitroglycerin (NTG) acts directly on vascular smooth muscle to 
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elicit dilation (Fung, Chung, Bauer, Chong, & Kowaluk, 1992). Therefore, 
administration of sublingual NTG can be used to measure endothelium-
independent dilation and contrast it with the endothelium-dependent dilatation 
occurring as a result of the NO released in response to shear stress (D. 
Celermajer et al., 1992b).  Acquisition of ultrasound images reflecting response 
to NTG should be repeated no earlier than ten minutes after reactive hyperemia 
in order to reestablish baseline conditions (Corretti et al., 2002). Peak dilation is 
reached about 3 to 4 minutes after a single high dose of NTG is administered 
(Corretti et al., 2002). Percent changes in diameter after administration of NTG, 
or nitroglycerin mediated-dilation (NMD) can be calculated in the same manner 
as FMD (%) values.  
(2)  𝑁𝑀𝐷 (%) =
(𝑝𝑒𝑎𝑘 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟) − (𝑝𝑟𝑒 − 𝑁𝑇𝐺 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)
(𝑝𝑟𝑒 − 𝑁𝑇𝐺 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)
 × 100 
Since NTG acts directly on vascular smooth muscle, changes in NMD (%) after 
weight loss reflect variations in arterial compliance or vascular smooth muscle 
function, and not in endothelial function as demonstrated by differences in FMD 
(%) (Corretti et al., 2002). Therefore, FMD (%) and NMD (%) values can be 
compared to evaluate whether the differences in vasodilation are truly due to 
endothelial function, or if smooth muscle function or compliance are contributing 
factors.  
 Along with FMD (%) and NMD (%) measurements which evaluate 
macrovascular function, the change in hyperemic flow can also be determined to 
serve as a measure of microvascular endothelial function (T. J. Anderson et al., 
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2011).  Although reactive hyperemia is the stimulus for FMD, an independent 
association between reactive hyperemia and cardiovascular events has been 
established (Mitchell et al., 2004; Philpott et al., 2009). An analysis of data taken 
from the study on Firefighters and Their Endothelium (FATE) demonstrated a 
stronger correlation between the presence of cardiovascular risk factors and 
hyperemic flow, than between the presence of cardiovascular risk factors and 
FMD (Philpott et al., 2009).  
Doppler signal is returned as spectral trace of velocity versus time. Blood 
flow towards the transducer presents as a velocity above baseline and retrograde 
blood flow presents as velocity below baseline (Li, Hoskins, Anderson, & 
Mcdicken, 1993). The velocity above baseline can be analyzed to determine 
antegrade blood flow and velocity, before and after cuff deflation (Gill, 1985). The 
percent change in flow can be calculated and used as a measure of the extent of 
reactive hyperemia, an indicator of microvascular function. 
    (3)     ∆ ℎ𝑦𝑝𝑒𝑟𝑒𝑚𝑖𝑐 𝑓𝑙𝑜𝑤 (%) =  
(𝑃𝑒𝑎𝑘 𝑓𝑙𝑜𝑤)−(𝑝𝑟𝑒−𝑜𝑐𝑐𝑙𝑢𝑠𝑖𝑜𝑛 𝑓𝑙𝑜𝑤)
(𝑝𝑟𝑒−𝑜𝑐𝑐𝑙𝑢𝑠𝑖𝑜𝑛 𝑓𝑙𝑜𝑤)
 × 100 
Accurate analyses of FMD and hyperemic flow via ultrasound is 
dependent on subject preparation, appropriate ultrasound technology, trained 
sonographers, and thorough knowledge of the method. Several factors can 
influence FMD in individuals: exercise, vitamin supplementation, vasoactive 
medications, temperature, tobacco, caffeine, phase of menstrual cycle, 
postprandial state, and orthostatic changes (Corretti et al., 2002).  Care should 
be taken to avoid these factors for a period before the ultrasound, or these 
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factors should be controlled for in order to eliminate their impact on FMD values. 
Highly resolved ultrasound images which depict a clearly identifiable arterial wall 
are necessary to obtain accurate measurements of the arterial diameter (Corretti 
et al., 2002; Harris et al., 2010). This requires skilled sonographers and 
appropriate ultrasound equipment. A 10 to 14 MHz linear array probe is ideal to 
obtain clear two-dimensional images of the brachial artery (Corretti et al., 2002). 
Since the diameter of the artery can vary extensively throughout a cardiac cycle, 
it is necessary for ultrasound Doppler systems to have an integrated ECG, so 
that images can be captured at end diastole during each cardiac cycle (Harris et 
al., 2010). The Doppler sample gate should be placed as close to the vessel 
walls as possible, without including them, in order to obtain accurate velocity 
measurements, as blood flow is laminar and reduced close to the vessel wall 
(Harris et al., 2010). Measurement of FMD can be performed using edge 
detection software. This software stores only those images obtained during end-
diastole and allows for manual modification of the measurements (Harris et al., 
2010). 
 
Surgical Weight Loss Interventions 
 Weight reduction, particularly loss of body fat, corresponds to an 
improvement in most subjects in comorbidities associated with obesity (Cornier, 
Marshall, Hill, Maahs, & Eckel, 2011). Although obesity prevention is the ideal 
way to ensure optimal cardiovascular health, other weight loss interventions can 
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be undertaken to reduce the amount of body fat contributing to cardiovascular 
health risks (Cornier et al., 2011). Nonsurgical interventional methods include 
lifestyle changes such as diet, exercise, and behavioral therapy, as well as 
medications like orlistat, sibutramine, and metformin, or combinations of these 
various approaches (Avenell et al., 2004). However, these interventions have a 
high failure rate and even if initially successful, they often result in weight regain 
(Fruehbeck, 2015). If nonsurgical interventions fail to result in sustained weight 
loss, surgical interventions might be warranted (Wolfe, Kvach, & Eckel, 2016). 
 The National Institute of Health has specified the eligibility for surgical 
weight loss interventions to include morbidly obese patients with BMI (kg/m2) 
>40, patients with BMI 35 to 40 with associated comorbidities, and certain 
patients with BMI 30 to 35 with type 2 diabetes mellitus. (Fruehbeck, 2015; 
Kuczmarski & Flegal, 2000) If patients meet this BMI criteria and medical therapy 
and lifestyle interventions fail, other considerations must be made in order to 
qualify for bariatric surgery. As with any surgical procedure, surgical risk must be 
assessed. Pre-surgical health conditions such as pulmonary disease, 
cardiovascular disease, and systemic disease must be taken into account before 
deciding on surgery. However, the short term surgical risks should be weighed 
against the long-term health consequences of obesity and its associated 
comorbidities (Flum et al., 2009). Patients should also be screened for the ability 
and motivation to commit to long-term medical management and willingness to 
reduce their energy intake (Saltzman et al., 2005). Psychological evaluation 
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should also be performed to assess for substance abuse, or other disorders 
which might contraindicate surgery (Wolfe et al., 2016). 
 Various types of surgical weight loss procedures exist, and the type of 
procedure a patient undergoes will depend on patient assessment and 
preference of the surgeon  (Fruehbeck, 2015). These procedures were initially 
classified according to their influence on food ingestion (Fried et al., 2014). 
Restrictive procedures reduce the size of the gastric pouch leading to earlier 
satiety, malabsorptive procedures limit the absorption of macronutrients, and 
mixed procedures include aspects of both restrictive and malabsorptive 
procedures (Fried et al., 2014; Fruehbeck, 2015). However, it is now recognized 
that this classification is an oversimplification and possibly inaccurate division of 
these procedures, and focus has shifted to the considerable metabolic changes 
these procedures induce (Fruehbeck, 2015). The effect of these procedures on 
neural and endocrine signaling pathways may play an important role in appetite 
and eating behaviors post-operatively (Wolfe et al., 2016). Standard bariatric 
procedures currently available for patients include Roux-en-Y Gastric Bypass 
(RYGB), Sleeve Gastrectomy, Biliopancreatic Diversion with or without Duodenal 
Switch, device implantation such as Adjustable Gastric Banding and Intermittent 
Vagal Blockade, as well as several procedures still under investigation (Fried et 
al., 2014; Ridley, 2005).  
 RYGB is the most widely performed surgical weight loss procedure in the 
United States (Mun, Blackburn, & Matthews, 2001). RYGB consists of a gastric 
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transection, creating a pouch in the stomach with the capacity of about one 
ounce, followed by a gastrojejunostomy. This creates an anastomoses between 
the stomach and the jejunum, allowing gastric contents to bypass up to 95% of 
the stomach, the duodenum, and 15 to 25 cm of the proximal jejunum (Brolin, 
2002; Fruehbeck, 2015). Sleeve gastrectomy is performed by resecting about 
80% of the stomach to create a tubular passing based on the lesser curvature of 
the stomach (Wolfe et al., 2016). Another method that is used infrequently due to 
higher complication rates, Biliopancreatic Diversion with Duodenal Switch 
combines gastric restriction by way of sleeve gastrectomy with intestinal 
malabsorption by creating an anastomosis between the proximal duodenum and 
the bypassed intestine (Brolin, 2002). Adjustable Gastric Banding, such as the 
LAP-BAND ® adjustable gastric banding system (LAGB, Allergan, Santa 
Barbara, CA), involves constriction of the size of the gastric pouch via placement 
of an adjustable band around the proximal stomach.  The band is connected to a 
subcutaneous port and can be inflated to increase the rate of gastric emptying 
(Brolin, 2002; Buchwald et al., 2009; Michaelson, Murphy, Gross, & Whitcup, 
2013). 
 Evaluation of data from long-term, prospective studies examining bariatric 
surgery outcomes has shown promising results. The Longitudinal Assessment of 
Bariatric Surgery (LABS) Consortium examined 2458 patients undergoing 
bariatric surgery at 10 different US hospitals, and showed significant weight loss 
in severely obese patients 3 years after surgery. There was, however, variability 
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in the trajectory of the weight loss experienced by these patients, as well as in 
blood pressure, diabetes, and lipid outcomes (Courcoulas et al., 2013). The 
Swedish Obese Subjects (SOS) trial simultaneously observed 2010 patients who 
underwent bariatric surgery and 2037 control patients who continued with non-
operative weight loss methods. This trial demonstrated a long-term reduction in 
overall mortality, in addition to decreased incidences of myocardial infarction, 
diabetes, and cancer in those subjects undergoing bariatric surgery as opposed 
to the control subjects receiving non-operative care (L. Sjostrom, 2013). Analysis 
also showed that high insulin and/or high glucose at baseline was a better 
predictor of favorable outcomes after bariatric surgery, than high baseline BMI  
(Sjöström et al., 2012). 
 
Specific Aims 
 This study seeks to evaluate the potential of bariatric surgery to improve 
vascular endothelial function. This will be accomplished by measuring FMD (%), 
NMD (%), and ∆ hyperemic flow (%) before surgery and comparing those values 
to measurements obtained at follow-up visits one, three, six, and twelve months 
after surgery. Changes in metabolic and anthropometric variables will also be 
measured to determine if the changes in any of these variables correlate with the 
changes in vascular function. Additionally, patients will be separated into two 
groups stratified by baseline plasma insulin levels, to determine if changes in 
endothelial function are differentially modified by baseline insulin status. 
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METHODS  
 
Study Participants  
Obese adults (BMI> 34.9 kg/m2; age 18-80) enrolled in a weight loss 
program at the Boston Medical Center Nutrition and Weight Management Clinic, 
scheduled to undergo bariatric surgery, were recruited and prospectively 
examined.  Primary care physicians refer patients to this program after a 
comprehensive evaluation of medical history, physical examination, EKG, and 
blood tests. Under the supervision of physicians and dietitians, individualized 
weight loss programs were established for the patients which consisted of 
behavioral, dietary, medical, and/or surgical treatments. Bariatric surgical 
treatments consisted of either RYGB, sleeve gastrectomy, or LAGB. Exclusion 
criteria for the study included patients with recent coronary syndromes, 
congestive heart failure, malignancy, systemic infection, acute illness, or 
pregnancy. The study was approved by the Boston Medical Center Institutional 
Review Board and all participants provided informed consent.  
 
Vascular Function Studies 
Vascular function studies were performed at baseline, before surgical 
intervention, as well as at follow-up visits 1 month, 3 months, 6 months, and 12 
months post-surgery. Patients were instructed to fast and refrain from smoking or 
ingesting caffeine beginning at midnight the night before the studies. Trained 
sonographers conducted the studies in quiet, temperature controlled rooms after 
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ten minutes of rest time for the patients. Hokanson SC10 blood pressure cuffs 
(Hokanson, Inc., Bellevue, Washington) with attached Welch Allyn Aneroid 
Sphygmomanometers (Welch Allyn Inc., Skaneateles Falls, New York) were 
applied to the right upper extremity, proximal to the antecubital fossa, and EKG 
leads were applied to right wrist, left wrist, and left clavicle, to correlate 
ultrasound measurements with end diastole of the cardiac cycle. SunTech 247B 
blood pressure cuffs (SunTech Medical, Morrisville, North Carolina) were applied 
to the left upper extremity in order to measure blood pressure at baseline prior to 
ultrasound. Images were obtained using noninvasive, standardized ultrasound 
method using Toshiba Powervision 6000 system (Toshiba Medical, Tustin, 
California). Doppler imaging was set up to open the gate to the width of the 
lumen and optimal 2-dimensional brachial artery images were acquired before 
measurements were recorded. Fifteen brachial artery diameter images and ten 
cycles of Doppler images were recorded before cuff inflation. The 
sphygmomanometer cuff on the right upper extremity was inflated to 50mmHg 
greater than systolic blood pressure, until vascular occlusion was achieved. After 
five minutes of occlusion, the cuff was deflated and ten cycles of Doppler were 
immediately captured. Doppler was then switched back to 2D and scans were 
continuously recorded for two minutes.  
Patients with systolic blood pressure less than 110mmHg, current 
headache, history of migraines, or use of Viagra, Levitra, or Cialis within the 
week prior were excluded from NTG-mediated dilation measurements. Ten 
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minutes post cuff deflation, fifteen 2D baseline images of the brachial artery were 
recorded. Then, 0.4 mg of sublingual NTG was administered to eligible study 
participants. Two minutes and fifteen second after administration, or after 
complete dissolution of the NTG, 60 seconds of 2D images were recorded. Blood 
pressures were recorded again after vascular measurements were completed.  
Two-dimensional images were converted for measurement using Vascular 
Converter for Research (Medical Imaging Applications LLC, Coralville, Iowa) and 
analyzed using Brachial Analyzer for Research (Medical Imaging Applications 
LLC, Coralville, Iowa) edge detection software. For each vascular study, ten 
baseline images were measured manually and the results averaged to obtain 
pre-FMD diameter (mm).  
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Figure 1. Pre-occlusion measurement of brachial artery diameter. Ultrasound image 
from a patient’s follow-up visit 12 months after bariatric surgery, measured to determine 
the pre-occlusion arterial diameter at this visit. The region of interest (ROI) is defined by 
the green line and the original detected edge was adjusted to fit the diameter, indicated 
by the red line. The red line was positioned between the intima and the media, just 
outside of the intima, to give a pre-occlusion diameter of 3.58 mm. This was one of ten 
pre-FMD images measured to determine a mean pre-occlusion diameter, which was 
used to calculate FMD (%). Ultrasound images were taken using Toshiba Powervision 
6000 system (Toshiba Medical, Tustin, California) and converted for measurement using 
Vascular Converter for Research (Medical Imaging Applications LLC, Coralville, Iowa). 
This screenshot was taken after measurement using Brachial Analyzer for Research 
(Medical Imaging Applications LLC, Coralville, Iowa).  
 
Images acquired from 55-65 seconds into hyperemia were also manually 
measured and averaged to obtain peak diameter (mm) after inflation. 
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Figure 2. Post-deflation measurement of brachial artery diameter. Ultrasound image 
from the same patient and visit as that in Figure 1, measured to determine the arterial 
diameter after deflation of the sphygmomanometer cuff and initiation of reactive 
hyperemia. Measured as in Figure 1 to obtain a diameter of 4.01mm. This was one of 
ten images measured and averaged to obtain a mean peak diameter, which was used to 
calculate FMD (%). Ultrasound images were taken using Toshiba Powervision 6000 
system (Toshiba Medical, Tustin, California) and converted for measurement using 
Vascular Converter for Research (Medical Imaging Applications LLC, Coralville, Iowa). 
This screenshot was taken after measurement using Brachial Analyzer for Research 
(Medical Imaging Applications LLC, Coralville, Iowa).  
 
The mean values calculated for post-occlusion and peak diameter were then 
used to calculate FMD (%).  
 Similar measurements were repeated to determine the percent change in 
diameter following administration of nitroglycerin. Ten pre-NTG images were 
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measured manually and the results averaged to obtain a mean pre-NTG 
diameter (mm).  
 
Figure 3. Pre-NTG brachial artery diameter measurement. Ultrasound image of the 
brachial artery at a patient’s three month post-operative follow-up visit, measured to 
determine a pre-NTG arterial diameter for NMD (%). Measured as in Figure 1 to obtain a 
diameter of 5.09 mm. This was one of ten images measured and then averaged to 
obtain a mean pre-NTG diameter, which was used to calculate NMD (%). Ultrasound 
images were taken using Toshiba Powervision 6000 system (Toshiba Medical, Tustin, 
California) and converted for measurement using Vascular Converter for Research 
(Medical Imaging Applications LLC, Coralville, Iowa). This screenshot was taken after 
measurement using Brachial Analyzer for Research (Medical Imaging Applications LLC, 
Coralville, Iowa). 
 
The images taken after administration of the NTG were then measured to obtain 
peak diameter. Twenty seconds were counted from the initial time in the first 
frame of the images after administration of NTG, and ten measurements were 
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manually measured from that new time point. These ten measurements were 
averaged to obtain a mean peak diameter (mm).  
 
Figure 4. Post-NTG brachial artery diameter measurement. Ultrasound image of the 
brachial artery from the same patient and visit in Figure 3, measured to determine a 
peak arterial diameter after administration of NTG. This image was taken about 2 
minutes and 15 seconds after administration of sublingual NTG. Measured as in Figure 1 
to obtain a diameter of 5.87 mm. This was one of ten images measured and averaged to 
obtain a mean peak diameter, which was used to calculate NMD (%). Ultrasound images 
were taken using Toshiba Powervision 6000 system (Toshiba Medical, Tustin, 
California) and converted for measurement using Vascular Converter for Research 
(Medical Imaging Applications LLC, Coralville, Iowa). This screenshot was taken after 
measurement using Brachial Analyzer for Research (Medical Imaging Applications LLC, 
Coralville, Iowa). 
 
The measured values for mean pre-NTG diameter and mean peak diameter were 
then used to calculate the NMD (%). 
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Doppler images were analyzed using ImageJ (Rasband, 1997). Positive 
flow of the Doppler waveform was traced and the velocity area (N; meters) was 
recorded for five cycles pre-occlusion.  
 
Figure 5. Pre-occlusion velocity area (N) measurement. Image of the Doppler 
waveform returned for brachial artery pre-occlusion blood flow. This image is from the 
same patient and follow-up visit as Figure 1, and this blood flow corresponds to the 
diameter measurement in Figure 1. The outline of the velocity-time curve for one cardiac 
cycle was traced, as indicated in yellow. ImageJ calculated the area of the curve under 
this trace to give a value for N. Five N values were measured using consecutive cardiac 
cycles before occlusion, and averaged to give a mean pre-occlusion N value. This value 
was then used to calculate pre-occlusion hyperemic flow. Doppler images were obtained 
using Toshiba Powervision 6000 system (Toshiba Medical, Tustin, California). This 
screenshot was taken after measurement using ImageJ software (Rasband, 1997).  
 
Measurements of the distance between peaks of the first six waveforms were 
also recorded (RR; in seconds).  
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Figure 6. Pre-occlusion peak-peak (RR) measurement. Image of the Doppler 
waveform returned for pre-occlusion brachial artery blood flow, from same patient in 
Figure 1. A straight line was drawn from the peak flow from one cardiac cycle to the 
peak flow of the subsequent cardiac cycle to obtain the peak-peak measurement (RR). 
Five RR measurements were obtained using consecutive cardiac cycles before 
occlusion, and averaged to give a mean pre-occlusion RR value. This RR value was 
then used to calculate pre-occlusion hyperemic flow. Doppler images were obtained 
using Toshiba Powervision 6000 system (Toshiba Medical, Tustin, California). This 
screenshot was taken after measurement using ImageJ software (Rasband, 1997).  
 
The area (N) and peak-peak (RR) measurements were repeated for the first five 
cycles post cuff deflation. 
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Figure 7. Post-deflation velocity area (N) measurement. Image of the Doppler 
waveform returned for brachial artery blood flow during reactive hyperemia, after release 
of the sphygmomanometer cuff. This image is also from the patient in Figure 1, and 
measurements correspond to peak diameter measurements in Figure 2. The velocity-
time curve was traced for one cardiac cycle and ImageJ was used to calculate the area 
under this trace (N). Five N values were measured and calculated, beginning with the 
first cardiac cycle and indication of blood flow after deflation of the cuff. These five N 
values were averaged to obtain a mean post-deflation N value. This mean post-deflation 
N value was then used to calculate peak hyperemic flow. Doppler images were obtained 
using Toshiba Powervision 6000 system (Toshiba Medical, Tustin, California). This 
screenshot was taken after measurement using ImageJ software (Rasband, 1997).  
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Figure 8. Post-Deflation peak-peak (RR) measurement. Image of the Doppler 
waveform returned for brachial artery blood flow, after deflation of the 
sphygmomanometer from same patient in Figure 1. A straight line was drawn from the 
peak flow from one cardiac cycle to the peak flow of the subsequent cardiac cycle to 
obtain the peak-peak measurement (RR). Five RR measurements were obtained using 
the consecutive cardiac cycles immediately after cuff deflation, and averaged to give a 
mean post-deflation RR value. This RR value was then used to calculate peak 
hyperemic flow. Doppler images were obtained using Toshiba Powervision 6000 system 
(Toshiba Medical, Tustin, California). This screenshot was taken after measurement 
using ImageJ software (Rasband, 1997).  
 
The five measured values for N and RR obtained before and after cuff deflation 
were averaged to determine the mean area under the trace (N) and mean peak-
peak values (RR). One measurement from 0 to 2 m/s (L; meters) was recorded 
to calibrate these measurements.  
 25 
 
Figure 9. Calibration measurement (L) for flow calculations. One measurement was 
taken on the returned Doppler waveform for blood flow, from 0 m/s to 2 m/s in order to 
calibrate for the number of pixels (L). This value was used in the calculations for 
baseline blood flow as well as peak blood flow. Doppler images were obtained using 
Toshiba Powervision 6000 system (Toshiba Medical, Tustin, California). This screenshot 
was taken after measurement using ImageJ software (Rasband, 1997).  
 
The means of N and RR, as well as the measured value of L and the baseline 
diameter (D) were used to calculate the blood flow and velocity for both pre-
occlusion and post-deflation using the following equations (Chung et al., 2009): 
(1)  𝑓𝑙𝑜𝑤 =
𝑁
𝐿×𝑅𝑅
 × 𝐷 × 𝐷 × 94.2  
(2) 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =
𝐹𝑙𝑜𝑤
𝐷 ×𝐷 ×0.47
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The calculated blood flows were used to find ∆ hyperemic flow (%) occurring as a 
result of reactive hyperemia.   
 
Metabolic and Anthropometric Measures 
Clinical history, current medications, and coronary risk factors were 
documented at initial patient appointment. Coronary risk factors recorded 
included hypercholesterolemia (total cholesterol>200 mg/dL and/or requiring 
prescription), hypertension requiring prescription, coronary artery disease, 
familial hypercholesterolemia in a first degree relative before the age of 60, 
diabetes mellitus (type I or II; insulin dependent), smoking, ethanol consumption, 
renal disease, and history of migraines. Height, weight, BMI, waist and hip 
circumference, systolic and diastolic blood pressure, and changes to medications 
were documented at each visit. Measurements of weight and height were taken 
using an Ohaus ES 200L Balance (Ohaus Corporation, Parsippany, NJ) and 
blood pressure measurements were taken using a SunTech 247B blood pressure 
cuff (SunTech Medical, Morrisville, North Carolina). Fasting blood samples were 
taken prior to vascular function studies being performed. Biochemical analyses of 
the blood samples included assessment of glycosylated hemoglobin, C-reactive 
protein, glucose, plasma insulin, HOMA-IR, cholesterol (total, HDL, and LDL), 
creatinine (including GFR), and triglycerides.  
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Statistical Analyses 
 Data was analyzed using SAS software, Version 9.4 of the SAS system 
for Windows (Copyright © 2013, SAS Institute Inc., Cary, North Carolina). 
Changes in FMD (%), NMD (%), ∆ hyperemic flow (%), and clinical parameters 
over time were determined using Generalized Estimating Equations (GEE). 
Descriptive statistics for the analyzed variables, as well as for demographic 
information and comorbidities were calculated. Clinical parameters were 
evaluated for an effect on the vascular endothelial function variables. A post hoc 
analysis was performed to determine if improvements in endothelial function are 
differentially modified by baseline plasma insulin status. An arbitrary value of 12 
µIU/ml was assigned as the limit for the low baseline plasma insulin group (n = 
206), while patients with baseline plasma insulin levels > 12 µIU/ml were 
assigned to the high baseline plasma insulin group (n = 206). This value of 12 
µIU/ml was used as a cutoff in a previous study, which demonstrated baseline 
plasma insulin level to be an important determinant of the benefit of bariatric 
surgery to improve endothelial function (Bigornia et al., 2013). Descriptive 
statistics on the primary variables of interest (vascular endothelial function 
variables) were also stratified into high and low baseline plasma insulin groups. 
Analyses of the difference in outcome between these two groups were also 
performed using GEE. P values < 0.05 were considered significant.  
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RESULTS 
 
Study Population 
 A total of 375 patients were enrolled in this study. Patients were between 
the ages of 32 and 51, with a mean age of 41.76 ± 12.35 years. Mean baseline 
BMI was 45.64 ± 8.36 and 79.73% of patients (n=299) identified as female. Over 
three quarters of the patients underwent Roux-en-Y gastric bypass surgery 
(n=317; 84.53%), 12.53% underwent sleeve gastrectomy (n=47), and 2.93% 
underwent LAP-BAND ® surgery (n=11).  
 
 
Figure 10. Types of Bariatric Surgery Performed on Study Population by 
Percentage  
 
Roux-en-Y
85%
Sleeve Gastrectomy
12%
LAP-BAND®
3%
Surgery Type
Roux-en-Y Sleeve Gastrectomy LAP-BAND®
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Table 1. Baseline Descriptive Statistics for Study Population – Categorical 
Variables 
Variable Frequency Percentage 
Surgery Type RYGB 
LAP-BAND® 
Sleeve 
Gastrectomy 
317 
11 
47 
84.53 
2.93 
12.53 
Gender Male 
Female 
63 
299 
16.8 
79.73 
Race White 
Black 
Native American 
Other 
195 
97 
1 
82 
 
52 
25.87 
0.27 
21.87 
Cigarette Smoking (current or past) Yes 
No 
 
144 
217 
 
38.4 
57.87 
 
Metabolic Syndrome Yes 
No 
 
174 
124 
 
46.4 
33.07 
 
Coronary Artery Disease Yes 
No 
 
20 
343 
 
5.33 
91.47 
 
Family History of Coronary Artery 
Disease 
Yes 
No 
 
117 
239 
 
31.2 
63.73 
 
Hypertension Yes 
No 
 
177 
186 
 
47.2 
49.6 
 
Diabetes Type 1 
Type 2 
No 
 
4 
124 
236 
 
1.07 
33.07 
62.93 
 
Hypercholesterolemia Yes 
No 
 
120 
245 
 
32 
65.33 
 
Post-Menopausal Post-Menopausal 
Pre-Menopausal 
N/A 
 
50 
159 
149 
 
13.33 
42.4 
39.73 
 
Categorical variables are expressed as frequency and percentage of the total study 
population (n=375). 
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Table 2. Baseline Descriptive Statistics for Study Population – Continuous 
Variables 
Variable Mean Standard 
Deviation 
Median Interquartile 
Range 
Range 
Height, in 65.25 
 
3.61 65 62-67 
 
53-78 
Weight, lbs 276.36 
 
55.02 262.5 238-304.6 175.3-
548.6 
Waist 
Circumference, cm 
49.33   7.09 48.5 44-53.5 34.5-75 
Systolic BP, mm Hg 130.8  13.99 129.5 121-138 104-200 
Diastolic BP, mm Hg 74.12  
 
10.52 73 67-80 49-117 
Hip Circumference, 
cm 
54.12  5.96 53.5 50-57 42-88 
Cholesterol, total, 
mg/dl 
187.4  38.71 181.5 160-209 91-354 
HDL, mg/dl 46.61  13.6 44.5 39-52 25-165 
LDL, mg/dl 115.17  33.54 112.5 93-135 10-292 
Triglycerides, mg/dl 129.09  74.93 109 79-161 31-548 
Glucose, mg/dl 113.33  54.26 96 87-114 14-429 
Plasma Insulin, 
µIU/ml 
15.09  8.3 13.5 9-19 0.2-50 
HOMA-IR 4.19 3.27 3.24 2.24-5.12 0.04-
26.46 
HbA1C, % 6.26  1.66 5.8 5.4-6.4 4.2-15.4 
Hs CRP, mg/dl 9.86 9.93 7 3.5-13.4 0.2-88.9 
CRP, mg/dl 1.88 2.38 1.2 0.7-2.2 0.2-16.9 
Creatinine, mg/dl 0.81  0.23 0.76 0.69-0.85 0.37-2.75 
Urine Creatinine, 
mg/dl 
1542.22 
 
880.56 1411.9 955.9-1929 0.66-
4930 
BMI, kg/m2 45.59  8.11 43.59 40.38-48.85 32.19-
98.32 
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Vascular Endothelial Function after Bariatric Surgery 
Descriptive statistics for FMD (%), NMD (%), and ∆ hyperemic flow (%) at 
each visit are displayed in Tables 3, 4, and 5, respectively.  
Table 3. Descriptive Statistics for FMD (%) by visit 
Visit Mean Standard 
Deviation 
Median Interquartile 
Range 
Range 
Baseline 9.49 5.32 9.36 5.31-13.08 -3.29-25.72 
1 month follow-up 8.99 4.69 8.49 5.1-11.9 0.43-20.8 
3 months follow-up 10.31 5.13 9.9 7.06-12.97 -0.37-30.22 
6 months follow-up 10.91 4.94 10.73 7.49-13.08 0.52-23.85 
12 months follow-up 10.59 4.92 10.38 6.97-14.63 1.52-25.44 
 
Table 4. Descriptive Statistics for NMD (%) by visit 
Visit Mean Standard 
Deviation 
Median Interquartile 
Range 
Range 
Baseline 14.65 6.25 13.81 10.69-19.41 3.59-36.82 
1 month follow-up 14.97 5.64 15.44 11.53-18 6.54-26.7 
3 months follow-up 16.75 7.68 15.2 11.41-22.57 4.12-35.39 
6 months follow-up 15.68 6.1 14.85 12.05-19.9 4.68-27.73 
12 months follow-up 17.11 6.19 18.4 11.02-21.88 5.3-27.49 
 
Table 5. Descriptive Statistics for ∆ Hyperemic Flow (%) by visit 
Visit Mean Standard 
Deviation 
Median Interquartile 
Range 
Range 
Baseline 760.9 417.3 688.89 455.07-971.89 -99.13-2558.87 
1 month follow-up 900.88 432.5 828.99 590.73-1168.93 241.77-2310.85 
3 months follow-up 903.85 393.97 887.18 627.08-1103.69 -3.87-2099.15 
6 months follow-up 869.88 450.7 809.04 496.05-1208.46 162.58-2147.48 
12 months follow-
up 
943.19 416.87 895.35 647.2-1198.04 162.89-2408.5 
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The differences from baseline at each of the follow-up visits for FMD (%), NMD 
(%) and ∆ hyperemic flow (%) are given in Tables 6, 7, and 8, respectively. 
Table 6. Differences from Baseline for FMD (%) by Follow-up Visit 
Visit Mean Standard 
Deviation 
Median Interquartile 
Range 
Range 
1 month 
follow-up 
0.27 5.21 0.89 -2.92-3.47 -13.58-11.85 
3 months 
follow-up 
1.48 5.13 1.46 -1.46-4.84 -16.25-14.64 
6 months 
follow-up 
2.48 6.29 1.7 -1.13-6.92 -10.43-15.5 
12 months 
follow-up 
1.28 5.49 1.11 -2.06-3.85 -23.47-17.14 
 
Table 7. Differences from Baseline for NMD (%) by Follow-up Visit 
Visit Mean Standard 
Deviation 
Median Interquartile 
Range 
Range 
1 month 
follow-up 
0.87 4.34 1.67 -2.44-4.16 -5.99-7.96 
3 months 
follow-up 
2.55 5.49 3.23 -0.79-6.14 -8-13.39 
6 months 
follow-up 
2.69 6.63 1.36 0-5.89 -8-16.32 
12 months 
follow-up 
4.26 6.23 3.66 0.55-8.59 -5.98-18.1 
 
Table 8. Differences from baseline for ∆ Hyperemic Flow (%) by Follow-up Visit 
Visit Mean Standard 
Deviation 
Median Interquartile 
Range 
Range 
1 month 
follow-up 
64.47 541.97 104.83 -220.55- 410.74 -1175.52-1108.43 
3 months 
follow-up 
194.18 485.89 185.27 -75.18-446.62 -1158.28-1622.93 
6 months 
follow-up 
190.77 557.04 190.46 -192.9-448.13 -913.37-1567.18 
12 months 
follow-up 
262.1 519.97 260.39 -58.79-503.95 -1039.33-1671.24 
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Analysis of the changes in FMD (%), NMD (%), and ∆ hyperemic flow (%) over 
time are given in Table 9.  
Table 9. GEE Estimates of One Month Change in Outcome 
Variable Estimate Confidence Interval p value  
FMD (%) 0.1143 0.0446-0.1839 0.0013 
NMD (%) 0.304 0.1429-0.4652 0.0002 
∆ hyperemic flow (%) 15.6897 8.1525-23.2269 < .0001 
Estimates and confidence intervals for a one month change in the outcome. For 
example, a one month change is associated with a 0.1143 increase in FMD (%)  
  
As seen in Table 9, the values of FMD (%), NMD (%), and ∆ hyperemic flow (%) 
all increased significantly over time (p < 0.05 for all variables), with the change in 
hyperemic flow demonstrating the most significant change (p < .0001).  
 
Clinical Parameters after Bariatric Surgery 
The mean ± standard deviation and median for each continuous metabolic and 
anthropometric variable at each visit are given in Table 10. Additional descriptive 
statistics for these visits are given the Appendix.  
 
 
 
 
 
 
 
 
 
 
 
 34 
Table 10. Mean and Standard Deviation for Study Population – Continuous Clinical 
Variables. 
Variable Baseline 
Mean 
± SD 
(Median) 
 
1 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
3 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
6 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
12 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
Weight, lbs 276.36  
± 55.02 
(262.5)  
250.57 
± 50.4 
(235.4)  
 
229.61 
± 52.62 
(216)  
 
235.84 
± 66.63 
(213.3)  
199.1 
± 48.84 
(186.4)  
 
Waist 
Circumference, cm 
49.33  
± 7.09 
(48.5)   
47.77 
± 5.27 
(47.13)  
43.15 
± 6.96 
(42.25)  
 
44.74 
± 8.35 
(43.5)  
 
39.48 
± 7.14 
(39)  
 
Systolic BP, mm Hg 130.8  
± 13.99 
(129.5)  
124.71 
± 15.04 
(123)  
 
127.79 
± 16.5 
(126)  
 
127.03 
± 16.64 
(128) 
 
126.46 
± 18.2 
(125)  
 
Diastolic BP, mm 
Hg 
74.12  
± 10.52 
(73)  
 
72.01 
± 10.33 
(69)  
 
73.06 
± 10.11 
(72)  
 
72.07 
± 9.97 
(70)  
 
73.7 
± 10.33 
(71.5)  
 
Hip Circumference, 
cm 
54.12  
± 5.96 
(53.5)  
52.38 
± 5.06 
(52) 
 
49.07 
± 6.1 
(48)  
 
50.08 
± 6.85 
(49.5)  
 
45.6 
± 6.05 
(44.5)  
 
Cholesterol, total, 
mg/dl 
187.4  
± 38.71 
(181.5) 
171.63 
± 38.17 
(168) 
 
167.71 
± 35.87 
(162.5)  
 
176.17 
± 31.34 
(175)  
 
168.16 
± 32.33 
(165.5)  
 
HDL, mg/dl 46.61  
± 13.6 
(44.5)  
38.52 
± 8.04 
(38)  
 
42.23 
± 12.38 
(41)  
 
47.16 
± 12.88 
(46)  
 
52.52 
± 11.58 
(51)  
 
LDL, mg/dl 115.17  
± 33.54 
(112.5)  
111.64 
± 32.37 
(105)  
 
105.72 
± 30.09 
(103)  
 
108.55 
± 6.41 
(108.5)  
 
98.59 
± 27.63 
(97.5)  
 
Triglycerides, mg/dl 129.09  
± 74.93 
(109)  
107.23 
± 37.36 
(99)  
 
100.4 
± 39.45 
(91.5)  
 
100.66 
± 41.41 
(93) 
 
86.14 
± 39.07 
(77)  
 
Glucose, mg/dl 113.33  
± 54.26 
(96) 
97.85 
± 23.02 
(93)  
 
98.63 
± 33.25 
(89)  
 
95.38 
± 23.2 
(89)  
 
94 
± 28.46 
(88.5)  
 
Plasma Insulin, 
µIU/ml 
15.09 
± 8.3 
(13.5)  
7.92 
± 6.35 
(6)  
 
8.19 
± 5.62 
(7) 
 
7.26 
± 6.27 
(5.5) 
 
6.31 
± 4.94 
(5)  
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Variable Baseline 
Mean 
± SD 
(Median) 
 
1 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
3 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
6 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
12 mo. 
Follow-up 
Mean 
± SD 
(Median) 
 
HOMA-IR 4.19 
± 3.27 
(3.24)  
2 
± 1.8 
(1.5)  
 
2.04 
± 1.92 
(1.5)  
 
1.77 
± 1.69 
(1.29)  
 
1.48 
± 1.26 
(1.1)  
 
HbA1C, % 6.26  
± 1.66 
(5.8)  
5.76 
± 0.99 
(5.45)  
 
5.71 
± 0.97 
(5.5 ) 
 
5.59 
± 0.75 
(5.5) 
 
5.57 
± 0.91 
(5.4) 
Hs CRP, mg/dl 9.86 
± 9.93 
(7)  
6.58 
± 8.22 
(3)  
 
7.06 
± 8.35 
(4.1)  
 
4.04 
± 5.62 
(2.15)  
 
3.44 
± 6.78 
(1.3) 
CRP, mg/dl 1.88  
± 2.38 
(1.2) 
0.94  
± 0.97 
(0.6) 
1.66  
± 2.15 
(0.6) 
1.06  
± 1.51 
(0.2) 
0.38  
± 0.48 
(0.1)  
Creatinine, mg/dl 0.81  
± 0.23 
(0.76)  
0.75 
± 0.14 
(0.74)  
 
0.74 
± 0.19 
(0.7)  
 
0.69 
± 0.13 
(0.68)  
0.73 
± 0.2 
(0.7)  
Urine Creatinine, 
mg/dl 
1542.22 
± 880.56 
(1411.9)  
 
2825.25 
± 1386.19 
(2852)  
 
2278.27 
± 1124.39 
(2515)  
 
1944.9 
± 1371.21 
(1668)  
 
1392.97 
± 734.02 
(1248) 
 
BMI, kg/m2 45.59  
± 8.11 
(43.59)  
41.64 
± 7.3 
(40.66)   
 
37.56 
± 7.93 
(35.47)  
38.46 
± 10.01 
(36.54)  
32.82 
± 7.61 
(30.95)  
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The differences from baseline for the continuous metabolic and anthropometric 
variables are given in Table 11. Additional descriptive statistics for these 
differences are given the Appendix.  
Table 11. Differences from Baseline for Continuous Clinical Variables by Follow-
up Visit 
 
Variable 1 mo. Follow-
up 
Mean 
± SD 
(Median) 
3 mo. Follow-
up 
Mean 
± SD 
(Median) 
6 mo. Follow-
up 
Mean 
± SD 
(Median) 
12 mo. Follow-
up 
Mean 
± SD 
(Median) 
Weight, lbs -28.42  
± 10.91 
(-29.2)  
-47.83  
± 17.11 
(-48.9)  
-66.58  
± 31.69 
(-68.5)  
-82.07  
± 33.98 
(-76.8)  
Waist Circumference, 
cm 
-3.22  
± 1.98 
(-3.25)  
-6.44  
± 3.01 
(-6.5)  
-8.82  
± 4.06 
(-9)  
-10.74  
± 4.96 
(-10.25)  
Hip Circumference, 
cm 
-2.41  
± 1.82 
(-2.5)  
-5.04  
± 2.6 
(-5.5)  
-6.88  
± 3.24 
(-7)  
-9.66  
± 4.77 
(-8.75)  
Systolic BP, mm Hg -6.6  
± 16.22 
(-7.5)  
-4.07  
± 17.7 
(-4)  
-5.34  
± 19.86 
(-6)  
-3.82  
± 18.76 
(-4)  
Diastolic BP, mm Hg -0.76  
± 10.04 
(-0.5)  
-1.05  
± 10.45 
(-2)  
-0.42  
± 10.78 
(0)  
0.6  
± 10.52 
(0)  
Cholesterol, total, 
mg/dl 
-15.68  
± 35.03 
(-20)  
-17.03  
± 37.14 
(-19)  
-12.66  
± 32.36 
(-13.5)  
-13.9  
± 35.07 
(-15)  
HDL, mg/dl -8.17  
± 6.72 
(-7)  
-3.32  
± 11.08 
(-3)  
-0.08  
± 18.56 
(1)  
6.11  
± 14.23 
(6)  
LDL, mg/dl -4.76  
± 30.67 
(-12)  
-7.71  
± 33.2 
(-13)  
-7.02  
± 30.8 
(-3)  
-12.67  
± 32.48 
(-14)  
Triglycerides, mg/dl -16.36  
± 51.32 
(-4)  
-27.31  
± 63.63 
(-18)  
-38.02  
± 59.25 
(-22)  
-34.29  
± 56.44 
(-27)  
Glucose, mg/dl -10.85  
± 22.76 
(-10)  
-22.64  
± 57.38 
(-8.5)  
-17.48  
± 31.7 
(-8.5)  
-25.26  
± 55.86 
(-9.5) 
Plasma Insulin, µIU/ml -5.43  
± 6.63 
(-6)  
-7.65  
± 7.31 
(-7)  
-8.4  
± 7.8 
(-7)  
-8.48  
± 7.35 
(-7.5)  
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Variable 1 mo. Follow-
up 
Mean 
± SD 
(Median) 
3 mo. Follow-
up 
Mean 
± SD 
(Median) 
6 mo. Follow-
up 
Mean 
± SD 
(Median) 
12 mo. Follow-
up 
Mean 
± SD 
(Median) 
HbA1C, % -0.59  
± 0.76 
(-0.4)  
-0.78  
± 1.32 
(-0.4) 
-0.69  
± 0.73 
(-0.5)  
-0.83  
± 1.24 
(-0.5) 
Hs CRP, mg/dl -3.29  
± 11.68 
(-1.3) 
-3.63  
± 8.76 
(-3.1)  
-5.64  
± 6.19 
(-3.55)  
-6.67  
± 7.76 
(-5.2)  
 
CRP, mg/dl -0.48  
± 0.98 
(-0.6)  
-1.48  
± 1.93 
(1)  
-0.62  
± 0.82 
(-0.4)  
-0.5  
± 0.14 
(-0.4)  
Creatinine, mg/dl -0.03  
± 0.1 
(-0.01)  
-0.1  
± 0.16 
(-0.07)  
-0.07  
± 0.11 
(-0.07)  
-0.07  
± 0.12 
(-0.05)  
Urine Creatinine, 
mg/dl 
1302.28  
± 1535.63 
(1343)  
686.86  
± 1284.62 
(751.5) 
227.63  
± 1413.84 
(270)  
-173.43  
± 1036.91 
(-29)  
BMI, kg/m2 -4.72  
± 1.71 
(-4.67) 
-7.8  
± 2.62 
(-7.96)  
-10.92  
± 5.06 
(-11.9)  
-13.5  
± 5.36 
(-12.98)  
HOMA-IR -1.64  
± 2.02 
(-1.6)  
-2.72  
± 3.15 
(-1.86)  
-2.54  
± 2.53 
(-1.94)  
-2.8  
± 2.65 
(-2.07)  
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Associations between Vascular Function and Clinical Parameters 
The association between clinical parameters and FMD, NMD and hyperemic flow 
are given in Tables 12, 13, and 14, respectively. 
Table 12. GEE Estimates of Clinical Parameter Association with FMD 
Variable Estimate  Confidence Interval P 
Weight, lbs -0.0173  -0.0249, -0.0097 <.0001 
Systolic BP, mmHg -0.0188  -0.0431, 0.0055 0.1295 
Diastolic BP, mmHg -0.0108  -0.0504, 0.0288 0.5927 
Waist Circumference, cm -0.1619  -0.2337, -0.0901 <.0001 
Hip Circumference, cm -0.0515  -0.1348, 0.0319 0.2262 
Cholesterol, total, mg/dl -0.0102  -0.021, 0.0005 0.0623 
HDL, mg/dl 0.0036  -0.0375, 0.0447 0.8636 
LDL, mg/dl -0.002  -0.0149, 0.0109 0.7649 
Triglycerides, mg/dl -0.0156 -0.0212, -0.01 <.0001 
Glucose, mg/dl -0.0249  -0.0333, -0.0166 <.0001 
Plasma Insulin, µIU/ml -0.0559  -0.1037, -0.0081 0.0218 
HbA1C, % -0.8725  -1.1148, -0.6302 <.0001 
CRP, mg/dl -0.0981  -0.3691, 0.1728 0.4778 
HsCRP, mg/dl -0.0136  -0.0507, 0.0234 0.4711 
Creatinine, mg/dl -4.7228  -6.3634, -3.0821 <.0001 
Urine Creatinine, mg/dl 0.0002  -0.0001, 0.0006 0.1706 
BMI, kg/m2 -0.0477 -0.0975, 0.002 0.0602 
HOMA-IR -0.2919  -0.4103, -0.1735 <.0001 
Estimates and confidence intervals for clinical variable association with FMD, via GEE. 
Estimates are beta coefficients on the scale of the outcome variable. For example, the -
0.0173 estimate for weight indicates that one lb higher weight corresponds to .0173 
lower FMD.  
 
 
As shown in Table 12, weight, waist circumference, triglycerides, glucose, HbA1C, 
creatinine, and HOMA-IR (p values < 0.0001), as well as plasma insulin (p = 
0.0218), all demonstrated a significant association with FMD.  
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Figure 11. GEE Estimates of Clinical Parameter Association with FMD. Estimates 
and confidence intervals for clinical variable association with FMD, via GEE. Estimates 
and Confidence intervals are presented per one standard deviation of the predictor. A 
negative values estimate indicates that a higher value for the clinical variable is 
associated with a lower value of FMD.  
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Table 13. GEE Estimates of Clinical Parameter Association with NMD 
Variable Estimate  Confidence Interval 
P 
Weight, lbs -0.0214 -0.0399, -0.0028 0.0237 
Systolic BP, mmHg -0.0361 -0.0848, 0.0127 0.1468 
Diastolic BP, mmHg -0.0675 -0.1351, 0.0001 0.0502 
Waist Circumference, cm -0.229 -0.4131, -0.0449 0.0147 
Hip Circumference, cm -0.1452 -0.3432, 0.0528 0.1506 
Cholesterol, total, mg/dl -0.03 -0.0528, -0.0073 0.0097 
HDL, mg/dl -0.0433  -0.1073, 0.0207 0.1846 
LDL, mg/dl -0.0274  -0.0549, 0.0002 0.0514 
Triglycerides, mg/dl -0.0105  -0.0251, 0.0041 0.1578 
Glucose, mg/dl -0.0188  -0.0491, 0.0115 0.2247 
Plasma Insulin, µIU/ml -0.0649  -0.1952, 0.0653 0.3283 
HbA1C, % -0.5596 -1.3511, 0.2319 0.1659 
CRP, mg/dl -1.8397  -3.0687, -0.6107 0.0033 
Hs CRP, mg/dl -0.2727  -0.4551, -0.0903 0.0034 
Creatinine, mg/dl -6.9515  -12.8765, -1.0265 0.0215 
Urine Creatinine, mg/dl 0.0005  -0.0001, 0.0011 0.0861 
BMI, kg/m2 -0.0934  -0.2181, 0.0313 0.1421 
HOMA-IR -0.1307  -0.5851, 0.3238 0.5731 
Estimates and confidence intervals for clinical variable association with NMD, via GEE. 
Estimates are beta coefficients on the scale of the outcome variable. For example, the -
0.0214 estimate for weight indicates that one lb higher weight corresponds to .0214 
lower NMD.  
 
As shown in Table 13, weight (p = 0.0237), waist circumference (p = 0.0147), 
total cholesterol (p = 0.0097), CRP (p = 0.0215), Hs CRP (p = 0.0034), and 
creatinine (p = 0.0215) all demonstrated a significant association with NMD. 
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Figure 12. GEE Estimates of Clinical Parameter Association with NMD. Estimates 
and confidence intervals for clinical variable association with NMD, via GEE. Estimates 
and Confidence intervals are presented per one standard deviation of the predictor. A 
negative values estimate indicates that a higher value for the clinical variable is 
associated with a lower value of NMD.  
 
 
 
 
 
 
 
 
-7.5 -5.0 -2.5 0.0 2.5 5.0 7.5
NMD
Weight
SBP
DBP
Waist Circumference
Hip Circumference
Cholesterol
HDL
LDL
TG
Glucose
Plasma Insulin
HgAIC
CRP
HsCRP
Creatinine
Urine Creatinine
BMI
HOMA
 42 
Table 14. GEE Estimates of Clinical Parameter Association with ∆ Hyperemic Flow 
Variable Estimate  Confidence Interval P 
Weight, lbs -1.2323  -1.946, -0.5187 0.0007 
Systolic BP, mmHg -2.1032  -4.6442, 0.4378 0.1048 
Diastolic BP, mmHg -1.4578  -5.428, 2.5124 0.4717 
Waist Circumference, cm -11.8484  -16.8018, -6.895 <.0001 
Hip Circumference, cm -8.3533  -14.1449, -2.5616 0.0047 
Cholesterol, total, mg/dl -0.0921  -1.0308, 0.8466 0.8475 
HDL, mg/dl 2.3963  -0.6007, 5.3933 0.1171 
LDL, mg/dl 0.256  -0.8234, 1.3354 0.6421 
Triglycerides, mg/dl -1.1167  -1.6184, -0.615 <.0001 
Glucose, mg/dl -1.4821  -2.1082, -0.856 <.0001 
Plasma Insulin, µIU/ml -12.3733  -17.2173, -7.5293 <.0001 
HbA1C, % -41.0361  -61.839, -20.2331 0.0001 
CRP, mg/dl 2.6788  -35.4919, 40.8495 0.8906 
HsCRP, mg/dl -4.7724  -9.2432, -0.3015 0.0364 
Creatinine, mg/dl -243.3037  -399.9151, -86.6923 0.0023 
Urine Creatinine, mg/dl 0.0073  -0.0279, 0.0424 0.6848 
BMI, kg/m2 -7.5833  -12.6394, -2.5272 0.0033 
HOMA-IR -35.7062  -46.3041, -25.1083 <.0001 
Estimates and confidence intervals for clinical variable association with ∆ hyperemic 
flow, via GEE. Estimates are beta coefficients on the scale of the outcome variable. For 
example, the -1.2323 estimate for weight indicates that one lb higher weight corresponds 
to 1.2323 lower ∆ hyperemic flow.  
 
As shown in Table 14, weight (p = 0.0007), hip circumference (p = 0.0047), 
HbA1C (p = .0.0001), Hs CRP (p = 0.0364), creatinine (p = 0.0023), and BMI (p = 
.0033), as well as waist circumference, triglycerides, glucose, plasma insulin, and 
HOMA-IR (p values <.0001) all demonstrated a significant association with the 
change in hyperemic flow. 
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Figure 13. GEE Estimates of Clinical Parameter Association with ∆ Hyperemic 
Flow. Estimates and confidence intervals for clinical variable association with ∆ 
hyperemic flow, via GEE. Estimates and Confidence intervals are presented per one 
standard deviation of the predictor. A negative values estimate indicates that a higher 
value for the clinical variable is associated with a lower value of ∆ hyperemic flow.  
 
Influence of Baseline Insulin Status 
Patients were dichotomized into two groups based off of baseline plasma 
insulin level, stratified by the median. Low baseline plasma insulin was 
considered ≤ 13.5 µIU/ml (n=168) and high baseline plasma insulin was 
considered > 13.5 µIU/ml (n=168).    
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Table 15. Baseline Descriptive Statistics Stratified by Baseline Plasma Insulin 
Level – Categorical Variables 
Variable High Insulin 
Frequency 
(Percentage) 
Low Insulin 
Frequency 
(Percentage) 
Surgery Type RYGB 
LAP-BAND® 
Sleeve Gastrectomy 
145 (86.31) 
5 (2.98) 
18 (10.71) 
141 (83.93) 
4 (2.38) 
23 (13.69) 
Gender Male 
Female 
134 (79.76) 
33 (19.64) 
144 (85.71) 
22 (13.1) 
Race White 
Black 
Native American 
Other 
99 (58.93) 
32 (19.05) 
0 (0) 
37 (22.03) 
78 (46.43) 
57 (33.93) 
1 (0.6) 
32 (19.04) 
Cigarette Smoking (current 
or past) 
Yes 
No 
68 (40.48) 
97 (57.74) 
61 (36.31) 
106 (63.1) 
Metabolic Syndrome Yes 
No 
94 (55.95) 
41 (24.4) 
67 (39.88) 
76 (45.24) 
Coronary Artery Disease Yes 
No 
10 (5.95) 
157 (93.45) 
5 (2.98) 
163 (97.02) 
Family History of Coronary 
Artery Disease 
Yes 
No 
61 (36.31) 
105 (62.5) 
48 (28.57) 
113 (67.26) 
Hypertension Yes 
No 
92 (54.76) 
75 (44.64) 
70 (41.67) 
98 (58.33) 
Diabetes Type 1 
Type 2 
No 
65 (38.69) 
2 (1.19) 
102 (60.71) 
44 (26.19) 
2 (1.19) 
122 (72.62) 
Hypercholesterolemia Yes 
No 
62 (36.9) 
106 (63.1) 
48 (28.57) 
120 (71.43) 
Post-Menopausal Post-Menopausal 
Pre-Menopausal 
N/A 
19 (11.31) 
71 (42.26) 
78 (46.43) 
27 (16.07) 
78 (46.43) 
63 (37.5) 
Categorical variables are expressed as frequency and percentage of the total study 
population (n=375). Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high 
baseline plasma insulin is considered > 13.5 µIU/ml.  
 
The mean ± standard deviation and median for the metabolic and anthropometric 
variables at each visit, stratified by a baseline plasma insulin level of 13.5 µIU/ml, 
are given in Table 16. Additional descriptive statistics for these values stratified 
by baseline plasma insulin level are given in the Appendix. 
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Table 16. Descriptive Statistics Stratified by Baseline Plasma Insulin Level, by visit 
– Continuous Clinical Variables 
Variable Baseline 
Insulin 
Status 
Baseline 
Mean ± 
SD 
Median 
1 mo. 
Follow-
up  
Mean ± 
SD 
Median 
3 mo. 
Follow-
up 
Mean ± 
SD 
Median 
6 mo. 
Follow-
up 
Mean ± 
SD 
Median 
12 mo. 
Follow-up 
Mean ± 
SD 
Median 
Weight, lbs Low 
 
267.37 ± 
48.08 
(254.4)  
244.5 ± 
46.88 
(232.7)  
223.13 ± 
43.81 
(212.55)  
220.33 ± 
52.97 
(201.2)  
195.52 ± 
45.55 
(182.6)  
 High 285.58 ± 
61.68 
(271.9)  
255.44 ± 
41.76 
(256.99)  
258.54 ± 
75.31 
(229.6)  
297.98 ± 
67.63 
(299.4)  
219.62 ± 
44.44 
(223.4)  
Waist 
Circumference, 
cm 
Low 
 
47.71 ± 
6.19 
(46.5)  
47.51 ± 
5.24 
(47)  
42.41 ± 
6.06 
(42) 
43 ± 6.47 
(43)  
39.24 ± 
7.09 
(38)  
 High 50.89 ± 
7.96 
(50)  
49 ± 5.8 
(50)  
47.22 ± 
10.61 
(46.25)  
56.75 ± 
10.89 
(53.75)  
43.33 ± 
7.57 
(39.75)  
Hip 
Circumference, 
cm 
Low 53.97 ± 
5.2 
(53.88)  
52.11 ± 
4.85 
(52)  
48.49 ± 
5.42 
(47.7)  
48.83 ± 
5.16 
(48.38)  
45.39 ± 
6.02 
(44.5)  
 High 54.47 ± 
6.81 
(53.5)  
53.88 ± 
6.23 
(54.5)  
51.92 ± 
8.98 
(49.75)  
59.46 ± 
9.92 
(56.5)  
48.92 ± 
7.31 
(49.75)  
Systolic BP, 
mmHg 
Low 131.45 ± 
13.99 
(130.5)  
 
124.68 ± 
14.5 
(123) 
 
128.8 ± 
17.67 
(126)  
 
126.34 ± 
15.15 
(129.5)  
 
126.36 ± 
18.73 
(124.5)  
 
 High 130.4 ± 
14.04 
(129)  
 
131.5 ± 
17.83 
(129)  
 
124.86 ± 
10.67 
(127)  
 
130 ± 
20.65 
(126)  
 
124.78 ± 
11.9 
(125)  
Diastolic BP, 
mmHg 
Low 75.18 ± 
9.76 
(74)  
72.39 ± 
10.54 
(69)  
73.87 ± 
10.3 
(73)  
71.84 ± 
8.97 
(69)  
73.95 ± 
10.63 
(72.5)  
 High 73.5 ± 
11.4 
(73)  
73.9 ± 
11.42 
(70)  
70.43 ± 
8.48 
(69)  
74.5 ± 
13.98 
(69)  
70.78 ± 
7.17 
(69)  
Cholesterol, 
total, mg/dl 
Low 188.2 ± 
37.36 
(184)  
168.71 ± 
34.57 
(167.5)  
165.24 ± 
33.17 
(162)  
170.86 ± 
27.82 
(170)  
165.92 ± 
27.6 
(165)  
 High 184.94 ± 
37.24 
(180)  
187.9 ± 
48.61 
(185.5)  
170.16 ± 
43.88 
(175)  
204.75 ± 
44.84 
(202.5)  
197.11 ± 
65.84 
(180)  
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean ± 
SD 
Median 
1 mo. 
Follow-
up  
Mean ± 
SD 
Median 
3 mo. 
Follow-
up 
Mean ± 
SD 
Median 
6 mo. 
Follow-
up 
Mean ± 
SD 
Median 
12 mo. 
Follow-up 
Mean ± 
SD 
Median 
HDL, mg/dl Low 48.77 ± 
11.7 
(47)  
38.31 ± 
8.14 
(37.5)  
41.79 ± 
12.98 
(40)  
46.5 ± 
10.28 
(46)  
53.01 ± 
11.75 
(51)  
 High 43.88 ± 
12.22 
(43)  
38.9 ± 
7.95 
(37.5)  
42.85 ± 
8.76 
(41.5)  
45.88 ± 
8.06 
(44.5)  
50.22 ± 
10.18 
(53)  
LDL, mg/dl Low 117.24 ± 
32.5 
(117)  
110 ± 
30.42 
(105)  
104.74 ± 
28.58 
(103)  
105.54 ± 
23.37 
(107.5)  
96.41 ± 
24.16 
(96)  
 High 113.94 ± 
32.95 
(111)  
123.1 ± 
38.12 
(115)  
103.5 ± 
32.97 
(87.5)  
133 ± 
35.84 
(139)  
122.44 ± 
52.26 
(109)  
Triglycerides, 
mg/dl 
Low 109.49 ± 
60.23 
(94)  
101.97 ± 
33.86 
(97.5)  
96.77 ± 
37.5 
(90)  
94.24 ± 
40.81 
(84)  
83.51 ± 
37.59 
(76)  
 High 135.16 ± 
66.78 
(119)  
128.8 ± 
39.67 
(131)  
109.6 ± 
49.57 
(93.5)  
129.5 ± 
40.04 
(135.5)  
122.22 ± 
46.73 
(115)  
Glucose, mg/dl Low 105.01 ± 
46.4 
(92)  
96.58 ± 
23.58 
(89)  
95.73 ± 
30.61 
(87)  
93.55 ± 
23.86 
(87)  
93.65 ± 
28.99 
(88)  
 High 116.49 ± 
53.68 
(101)  
110.4 ± 
19.07 
(106)  
102.2 ± 
25.77 
(92.5)  
109.13 ± 
22.54 
(103)  
98.22 ± 
26.09 
(93)  
Plasma Insulin, 
µIU/ml 
Low 8.98 ± 
3.17 
(9)  
5.85 ± 
3.28 
(6)  
6.49 ± 
3.14 
(6) 
5.14 ± 
2.78 
(4.5)  
5.26 ± 
2.59 
(5)  
 High 21.19 ± 
7.3 
(19)  
20.7 ± 
5.83 
(21)  
18.57 ± 
6.26 
(17)  
20.5 ± 
5.76 
(19)  
20 ± 7.7 
(15)  
HbA1C, % Low 6.05 ± 
1.42 
(5.6)  
5.79 ± 1 
(5.5)  
5.59 ± 
0.83 
(5.4)  
5.58 ± 
0.8 
(5.5)  
5.51 ± 
0.84 
(5.4)  
 High 6.32 ± 
1.71 
(5.9)  
5.78 ± 
0.98 
(5.65)  
6.01 ± 
1.31 
(5.65)  
5.81 ± 
0.6 
(5.9)  
6.39 ± 
1.44 
(5.9)  
HsCRP, mg/dl Low 9.39 ± 
11.27 
(6)  
6.59 ± 
8.48 
(2.9)  
6.89 ± 
8.56 
(3.8)  
3.54 ± 
5.37 
(1.75)  
3.28 ± 
6.73 
(1.2)  
 High 10.69 ± 
8.62 
(7.6)  
7.35 ± 
7.92 
(4.9)  
8.59 ± 
7.44 
(6.25)  
8.44 ± 
6.63 
(7.8)  
6.08 ± 
7.67 
(2.2)  
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean ± 
SD 
Median 
1 mo. 
Follow-
up  
Mean ± 
SD 
Median 
3 mo. 
Follow-
up 
Mean ± 
SD 
Median 
6 mo. 
Follow-
up 
Mean ± 
SD 
Median 
12 mo. 
Follow-up 
Mean ± 
SD 
Median 
CRP, mg/dl Low 1.31 ± 0.9 
(1.1)  
 
0.87 ± 
0.92 
(0.6)  
 
1.55 ± 
2.35 
(0.6)  
 
0.73 ± 
1.06 
(0.2)  
 
0.41 ± 
0.49 
(0.15)  
 
 High 2.14 ± 
2.82 
(1.2)  
1.45 ± 
1.63 
(1.45)  
2.25 ± 
2.47 
(2.25)  
2.2 ± 
2.83 
(2.2)  
0.1 ± 0.1 
(0.1)  
Creatinine, 
mg/dl 
Low 0.79 ± 
0.19 
(0.75)  
0.75 ± 
0.14 
(0.74)  
0.74 ± 
0.2 
(0.7)  
0.7 ± 
0.13 
(0.69)  
0.74 ± 0.2 
(0.7)  
 High 0.81 ± 
0.27 
(0.76)  
0.76 ± 
0.18 
(0.73)  
0.72 ± 
0.13 
(0.69)  
0.73 ± 
0.13 
(0.69)  
0.68 ± 0.1 
(0.68)  
Urine 
Creatinine, 
mg/dl 
Low 1575.47 ± 
954.26 
(1382.45)  
2957.52 
± 
1420.28 
(2908)  
2294.08 
± 
1185.85 
(2533.5)  
1986.48 
± 
1433.45 
(1778)  
1394.29 ± 
740.43 
(1251)  
 High 1557.51 ± 
817.42 
(1442)  
2397 ± 
1308.44 
(2009)  
2243.45 
± 911.1 
(2428.5)  
2236.99 
± 
1203.76 
(1874.5)  
1015.85 ± 
253.36 
(1015.85)  
BMI, kg/m2 Low 44.39 ± 
6.37 
(43.33)  
40.63 ± 
6.33 
(40.19)  
36.36 ± 
6.15 
(35.15)  
36.01 ± 
7.03 
(34.41)  
32.21 ± 
6.92 
(30.4)  
 High 47.05 ± 
9.59 
(44.06)  
44.32 ± 
7.74 
(44.44)  
42.93 ± 
11.88 
(41.15)  
48.62 ± 
10.63 
(45.42)  
36.64 ± 
7.71 
(35.15)  
HOMA-IR Low 2.27 ± 
1.14 
(2.24)  
1.4 ± 
0.82 
(1.3)  
1.59 ± 
1.13 
(1.35)  
1.17 ± 
0.63 
(1.09)  
1.21 ± 
0.68 
(1.05)  
 High 6.12 ± 
3.57 
(4.98)  
5.61 ± 
1.87 
(4.82)  
4.88 ± 
3.13 
(3.71)  
5.44 ± 
1.49 
(5.5)  
4.84 ± 2.1 
(3.61)  
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml.  
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The mean ± standard deviation and median for the differences from the baseline 
value for the metabolic and anthropometric variables, stratified by a baseline 
plasma insulin level of 13.5 µIU/ml are given in Table 17. Additional descriptive 
statistics for these values stratified by baseline plasma insulin level are given in 
the Appendix.  
 
Table 17. Differences from Baseline Stratified by Baseline Plasma Insulin Level, by 
Follow-up visit  
Variable Baseline 
Insulin 
Status 
1 mo. 
Follow-up 
Mean ± SD 
(Median) 
3 mo. Follow-
up 
Mean ± SD 
(Median) 
6 mo. Follow 
up 
Mean ± SD 
(Median) 
12 mo. 
Follow-up 
Mean ± SD 
(Median) 
Weight, lbs Low -29 ± 9.93 
(-29.7)  
-49.19 ± 14.72 
(-50)  
-71.39 ± 
24.16 
(-69.24)  
-83.6 ± 33.32 
(-77.8)  
 High -26.41 ± 9.64 
(-22.5)  
-39.16 ± 21.23 
(-41.2)  
-47.94 ± 
43.51 
(-49.5)  
-67.81 ± 
39.29 
(-59.6)  
Waist 
Circumference, 
cm 
Low 
 
-3.27 ± 1.99 
(-3.38)  
-6.68 ± 2.89 
(-7)  
-9.18 ± 3.77 
(-9.63)  
-10.83 ± 5.07 
(-10.5)  
 High -3.25 ± 2.04 
(-3)  
-5.04 ± 3.23 
(-5.5)  
-5.3 ± 5.65 
(-8)  
-8.85 ± 4.39 
(-8)  
Hip 
Circumference, 
cm 
Low 
 
-2.45 ± 1.92 
(-3)  
-5.31 ± 2.4 
(-5.5)  
-7.28 ± 2.65 
(-7)  
-9.84 ± 4.79 
(-8.88)  
 High -2.19 ± 1.29 
(-2)  
-3.32 ± 3.12 
(-4)  
-2.38 ± 5.46 
(-1.88)  
-5.55 ± 4.13 
(-6)  
Systolic BP, 
mmHg 
Low -6.13 ± 16.28 
(-7.5)  
-2.02 ± 17.21 
(-4)  
-6.02 ± 20.21 
(-5.5)  
-3.69 ± 18.7 
(-3)  
 High -6.5 ± 20.6 
(-4.5)  
-10.06 ± 18.23 
(-7)  
-1.5 ± 17.84 
(-6)  
-5.75 ± 18.68 
(-11)  
Diastolic BP, 
mmHg 
Low -1.16 ± 10.02 
(-1)  
-0.06 ± 10.16 
(-1)  
 
-0.6 ± 9.89 
(1)  
0.87 ± 10.52 
(0)  
 High 4.2 ± 11.72 
(3.5)  
-4.72 ± 10.43 
(-4.5)  
0.75 ± 12.85 
(1)  
-3.63 ± 9.88 
(-1)  
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Variable Baseline 
Insulin 
Status 
1 mo. 
Follow-up 
Mean ± SD 
(Median) 
3 mo. Follow-
up 
Mean ± SD 
(Median) 
6 mo. Follow 
up 
Mean ± SD 
(Median) 
12 mo. 
Follow-up 
Mean ± SD 
(Median) 
Cholesterol, 
total, mg/dl 
Low -20.21 ± 
32.24 
(-20.5)  
-18.56 ± 35.02 
(-19.5)  
-14.24 ± 
27.72 
(-13)  
-14.68 ± 
30.99 
(-14)  
 High 15.4 ± 40.95 
(7)  
-10.95 ± 37.38 
(-27)  
14.5 ± 38.88 
(15)  
-11.44 ± 
70.53 
(-22)  
HDL, mg/dl Low -8.52 ± 6.68 
(-7)  
-3.29 ± 11.92 
(-4)  
0.88 ± 7.15 
(0)  
6.54 ± 14.64 
(7)  
 High -6.2 ± 5.96 
(-7)  
-2.95 ± 6.6 
(-3)  
3 ± 7.15 
(1.5)  
2.11 ± 6.47 
(4)  
LDL, mg/dl Low -7.74 ± 27.56 
(-12.5)  
-9.1 ± 31.44 
(-14) 
-7.94 ± 27.06 
(-3)  
-13.63 ± 
29.57 
(-14)  
 High 17.4 ± 43.51 
(12)  
-6.45 ± 37.44 
(-15)  
12.88 ± 36.63 
(16.5)  
-7.44 ± 60.6 
(-24)  
Triglycerides, 
mg/dl 
Low -20.21 ± 
48.86 
(-8)  
-24.29 ± 61.44 
(-16)  
-39.55 ± 53.1 
(-25)  
-35.39 ± 
52.62 
(-28)  
 High 3.3 ± 62.9 
(9.5)  
-30.75 ± 67.7 
(-23.5)  
-6.25 ± 66.08 
(7)  
-30.11 ± 
99.25 
(-8)  
Glucose, mg/dl Low -12.18 ± 22.4 
(-10.5)  
-16.29 ± 42.76 
(-7)  
-17.14 ± 
25.21 
(-9)  
-19.49 ± 
37.78 
(-9)  
 High -1.33 ± 27.83 
(-1)  
-58.9 ± 95.6 
(-12)  
-9.29 ± 20.81 
(-5)  
-105.89 ± 
145.18 
(-16)  
Plasma Insulin, 
µIU/ml 
Low -5.97 ± 5.29 
(-6)  
-8.46 ± 6.96 
(-8)  
-9.66 ± 6.56 
(-9)  
-9.04 ± 6.74 
(-8)  
 High -2.2 ± 11.82 
(-2.5)  
-2.75 ± 7.66 
(-3)  
-1 ± 10.69 
(1)  
-0.63 ± 11.02 
(-0.5)  
HbA1C, % Low -0.59 ± 0.81 
(-0.3)  
-0.7 ± 1.08 
(-0.4)  
-0.69 ± 0.68 
(-0.5)  
-0.71 ± 0.97 
(-0.5)  
 High -0.58 ± 0.47 
(-0.45)  
-1.22 ± 2.32 
(-0.2)  
-0.87 ± 1.21 
(-0.3)  
-3.13 ± 3.02 
(-2.75)  
HsCRP, mg/dl Low -3.74 ± 12.7 
(-1.35)  
-3.88 ± 8.87 
(-3.25)  
-5.97 ± 6.45 
(-3.55)  
-6.75 ± 8.02 
(-5.25) 
 High -1.31 ± 5.22 
(-0.6)  
-2.1 ± 8.68 
(-2.95)  
-2.6 ± 2.98 
(-2.1)  
-5.77 ± 3.46 
(-5.85)  
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Variable Baseline 
Insulin 
Status 
1 mo. 
Follow-up 
Mean ± SD 
(Median) 
3 mo. Follow-
up 
Mean ± SD 
(Median) 
6 mo. Follow 
up 
Mean ± SD 
(Median) 
12 mo. 
Follow-up 
Mean ± SD 
(Median) 
CRP, mg/dl Low -0.58 ± 0.95 
(-0.6)  
-1.95 ± 2.69 
(-1)  
-0.9 ± 0.87 
(-0.5)  
-0.5 ± 0.14 
(-0.4)  
 High 0.05 ± 1.34 
(0.05)  
 
-1.05 ± 1.48 
(-1.05)  
 
-0.05 ± 0.35 
(-0.05)  
 
N/A* 
 
Creatinine, 
mg/dl 
Low -0.04 ± 0.1 
(-0.03)  
-0.11 ± 0.15 
(-0.08)  
-0.07 ± 0.12 
(-0.08)  
-0.06 ± 0.12 
(-0.05)  
 High -0.03 ± 0.12 
(-0.03)  
-0.06 ± 0.18 
(-0.02)  
-0.07 ± 0.1 
(-0.07)  
-0.11 ± 0.16 
(-0.02)  
Urine 
Creatinine, 
mg/dl 
Low 1574.09 ± 
1470.05 
(1773)  
614.29 ± 
1316.97 
(699)  
351.41 ± 
1352.53 
(272)  
-171.59 ± 
1046.89 
(-51.9) 
 High 886.25 ± 
1391.06 
(537)  
747.48 ± 
1209.27 
(596.5)  
70.83 ± 
1823.7 
(542)  
-511.7 ± 
1642.89 
(-511.7)  
BMI, kg/m2 Low -4.81 ± 1.54 
(-4.8)  
-7.99 ± 2.16 
(-7.96)  
-11.72 ± 3.72 
(-12.47)  
-13.76 ± 5.24 
(-13.18)  
 High -4.49 ± 1.37 
(-4.11)  
-6.56 ± 3.5 
(-6.93)  
-8.04 ± 7.23 
(-8.27)  
-11.07 ± 6.03 
(-10.23)  
HOMA-IR Low -1.85 ± 1.65 
(-1.71)  
-2.74 ± 3.09 
(-1.85)  
-2.94 ± 2.27 
(-2.42)  
-2.8 ± 2.49 
(-2.07)  
 High -0.24 ± 3.43 
(-0.79)  
-2.59 ± 3.6 
(-1.96)  
0.07 ± 2.74 
(0.6)  
-2.74 ± 4.55 
(-1.85)  
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. *No patient data available. 
 
The mean ± standard deviation and median for FMD (%), NMD (%), and ∆ 
Hyperemic Flow (%) at each visit, stratified by baseline plasma insulin level are 
given in Tables 18, 19, and 20, respectively. Additional descriptive statistics for 
these values stratified by baseline plasma insulin level are given in the Appendix. 
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Table 18. Descriptive Statistics Stratified by Baseline Plasma Insulin Level for 
FMD (%), by Visit 
Visit Low Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
High Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
Baseline 10.28 ± 5.18 
(9.81) 
9.16 ± 5.43 
(9.07) 
1 month follow-up 9.04 ± 4.74 
(7.75) 
9.45 ± 5.96 
(10.06) 
3 month follow-up 10.5 ± 5.02 
(9.98) 
10.88 ± 4.85 
(10.96) 
6 month follow-up 10.43 ± 4.83 
(10.36) 
13.9 ± 5.29 
(15.63) 
12 month follow-up 10.85 ± 5.03 
(10.74) 
9.21 ± 3.65 
(7.89) 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml.  
 
Table 19. Descriptive Statistics Stratified by Baseline Plasma Insulin Level for 
NMD (%), by Visit 
Visit Low Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
High Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
Baseline 15.39 ± 5.52 
(14.8) 
14.05 ± 7.01 
(12.69) 
1 month follow-up 15.41 ± 6.39 
(14.7) 
14.23 ± 3.08 
(15.53) 
3 month follow-up 17.11 ± 7.58 
(15.24) 
22.08 ± 11.45 
(20.64) 
6 month follow-up 16.39 ± 4.84 
(15.74) 
15.12 ± 11.4 
(12.05) 
12 month follow-up 17.32 ± 6.05 
(18.61) 
11.11 ± 11.11 
(11.11) 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml.  
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Table 20. Descriptive Statistics Stratified by Baseline Plasma Insulin Level for ∆ 
Hyperemic Flow (%), by Visit 
Visit Low Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
High Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
Baseline 856.69 ± 418.69 
(848.26) 
658.08 ± 366.93 
(571.32) 
1 month follow-up 922.63 ± 406.04 
(852.38) 
848.05 ± 676.36 
(672.39) 
3 month follow-up 934.63 ± 391.82 
(908.77) 
645.84 ± 324.42 
(584.19) 
6 month follow-up 912.9 ± 453.17 
(896.52) 
588.02 ± 320.07 
(679.94) 
12 month follow-up 951.21 ± 409.75 
(947.96) 
848.23 ± 375.24 
(829.45) 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml.  
 
The mean ± standard deviation and median for differences from baseline values 
for FMD (%), NMD (%), and ∆ Hyperemic Flow (%) at each follow-up visit, 
stratified by baseline plasma insulin level are given in Tables 21, 22, and 23, 
respectively. Additional descriptive statistics for these values stratified by 
baseline plasma insulin level are given in the Appendix. 
 
Table 21. Differences from Baseline Stratified by Baseline Plasma Insulin Level for 
FMD (%), by Follow-up Visit 
Visit Low Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
High Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
1 month follow-up 0.43 ± 5.55 
(1.2) 
0.84 ± 4.65 
(2.19) 
3 month follow-up 1.65 ± 5.09 
(1.54) 
0.73 ± 3.85 
(-0.66) 
6 month follow-up 1.36 ± 5.74 
(1.01) 
4.72 ± 4.76 
(3.02) 
12 month follow-up 1.24 ± 5.55 
(1.13) 
3.39 ± 6 
(2.62) 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml.  
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Table 22. Differences from Baseline Stratified by Baseline Plasma Insulin Level for  
NMD (%), by Follow-up Visit 
Visit Low Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
High Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
1 month follow-up 0.96 ± 4.12 
(2.3) 
-5.99 ± -5.99 
(-5.99) 
3 month follow-up 2.3 ± 5.54 
(2.88) 
4.78 ± 6.18 
(5.86) 
6 month follow-up 4.13 ± 7.54 
(2.59) 
1.56 ± 2.07 
(0.77) 
12 month follow-up 4.59 ± 6.43 
(4.11) 
0.55 ± 0.55 
(0.55) 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml.  
 
Table 23. Differences from Baseline Stratified by Baseline Plasma Insulin Level for 
∆ Hyperemic Flow (%), by Follow-up Visit 
Visit Low Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
High Baseline Plasma 
Insulin 
Mean ± SD 
(Median) 
1 month follow-up 96.74 ± 471.65 
(131.17) 
-1.92 ± 874.16 
(57.91) 
3 month follow-up 222.06 ± 483.22 
(218.92) 
-103.76 ± 362.8 
(-86.26) 
6 month follow-up 211.5 ± 567.43 
(190.7) 
-166.69 ± 526.14 
(-170.88) 
12 month follow-up 251.94 ± 520.82 
(268.44) 
298.91 ± 493.52 
(220.64) 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml.  
 
Analyses of the differences between the high and low baseline plasma insulin 
group is given in Table 24.  
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Table 24. GEE Estimates of One Month Change in Outcome Associated with High 
Baseline Plasma Insulin 
Variable Estimate Confidence Interval p value  
FMD (%) 0.1627 -0.0438, 0.3691 0.1226 
NMD (%) -0.1162 -0.5445, 0.3121 0.5949 
∆ hyperemic flow (%) 1.9425 -20.3086, 24.1935 0.8641 
Difference between high and low baseline insulin groups for a one month change of the 
outcome. For example, the high insulin group has a 0.1627 higher 1 month change in 
FMD (%) compared to the low insulin group. Low baseline plasma insulin is considered ≤ 
13.5 µIU/ml and high baseline plasma insulin is considered > 13.5 µIU/ml.  
 
 
As seen in Table 24, the p values for FMD (%) (p = 0.1226), NMD (%) (p = 
0.5949), and ∆ hyperemic flow (%) (p = 0.8641) are all > 0.05, indicating no 
significant difference between the high and low baseline plasma insulin groups.  
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DISCUSSION 
 
 This study demonstrated an increase in FMD (%), NMD (%), and ∆ 
hyperemic flow (%) after bariatric surgery, indicating an improvement in both 
macrovascular and microvascular function. The increase in hyperemic flow (p < 
0.0001) was more significant than the increase in FMD (p = 0.0013) and NMD (p 
= 0.0002). Weight, waist circumference, triglycerides, glucose, HbA1C, creatinine, 
and HOMA-IR (p values < 0.0001), as well as plasma insulin (p = 0.0218) all 
showed significant associations with FMD, implying that as these values 
decrease after bariatric surgery, macrovascular function improves. Change in 
hyperemic flow demonstrated significant associations with weight (p = 0.0007), 
hip circumference (p = 0.0047), waist circumference (p < 0.0001), HbA1C (p < 
0.0001), Hs CRP (p = 0.0364), creatinine (p = 0.0023), triglycerides (p < 0.0001), 
glucose (p < 0.0001), plasma insulin (p < 0.0001), HOMA-IR (p < 0.0001), and 
BMI (p = 0.0033), implying that microvascular function improves as these values 
decrease post-surgery.  
While other studies have been performed that evaluated the effect of 
weight loss on endothelial function, this study consisted only of patients who 
were treated via surgical intervention and was the largest cohort of bariatric 
surgery patients to be followed for assessment of endothelial function (Lupoli et 
al., 2016). Also, this study examined changes in both FMD (%) and ∆ hyperemic 
flow (%), as opposed to previous studies which only measured one of these 
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variables (Kararoudi et al., 2016; Lupoli et al., 2016; Martin-Rodriguez et al., 
2014).  
 The improvements in vascular endothelial function after bariatric surgery 
seen in this study are consistent with previous studies which established 
improvements in FMD or hyperemic flow in a smaller cohort of patients 
(Kararoudi et al., 2016; Nerla et al., 2012; Tschoner et al., 2013). Although no 
cardiovascular outcome data was analyzed in this study, the improvements in 
vascular endothelial function support findings from the SOS study which revealed 
a reduced number of cardiovascular events and mortality in obese persons after 
bariatric surgery, in comparison with patients who continued with non-surgical 
weight loss interventions (Sjöström et al., 2012).  
 Associations between the resolution of metabolic syndrome, as well as the 
improvement in insulin resistance after surgery have been tied to improvements 
in microvascular function (Kararoudi et al., 2016; Martin-Rodriguez et al., 2014). 
Improvements in insulin resistance have also been associated with 
improvements in macrovascular function (Bigornia et al., 2013). Multivariable 
analyses needs to be completed to evaluate independent associations for the 
clinical parameters in this study, adjusting for all other predictors in the model. 
Further analyses could support these previous findings and help define new 
eligibility guidelines for bariatric surgery. This might give a better understanding 
of which parameters, if any, are good predictors of improvements in vascular 
function. 
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 The stratification of vascular function variables by baseline plasma insulin 
level showed no significant difference between high and low insulin groups. This 
is inconsistent with previous studies which have shown a link between baseline 
insulin and vascular function improvement after weight loss, as well as data from 
the SOS study which suggested that baseline insulin is a better determinant of 
vascular function improvement than baseline BMI (T. J. Anderson, 2013; Bigornia 
et al., 2013; Sjöström et al., 2012). 
 
Study Limitations 
 This study has several limitations. It did not include any cardiac outcome 
data, but relied only on vascular endothelial function as a means of analyzing the 
cardiovascular benefits of bariatric surgery.  However, multiple outcomes studies 
have validated endothelial function as an acceptable measure of cardiac risk 
(Gokce, 2011). Also, this study was not-randomized. Patients and their care 
management teams determined the best approach to weight loss and selected 
the appropriate surgical procedure, preventing randomization. Many participants 
were lost to follow-up or were unable to attend all of their follow-up visits and only 
a small number of participants were able to take NTG, limiting the amount of 
NMD (%) data available for comparison to FMD (%) data.  Additionally, an 
arbitrary value was used to separate patients into high and low baseline plasma 
insulin subsets (low baseline insulin ≤13.5µIU/ml). Analyses of the SOS study 
showed high baseline plasma insulin level to be a good predictor of favorable 
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cardiovascular effects of bariatric surgery, however this study stratified patient by 
a baseline plasma insulin level of 17.0 µIU/ml. (L. Sjostrom, 2013; Lars Sjostrom 
et al., 2012) Therefore, further analyses will need to be performed to determine if 
stratification by a different baseline insulin level demonstrates a significant 
difference between high and low baseline insulin groups.  
 
Conclusions 
 The results of this study suggest that bariatric surgery improves 
macrovascular and microvascular endothelial function. Macrovascular 
improvement was associated with decreases in weight, waist circumference, 
triglycerides, glucose, HbA1C, creatinine, HOMA-IR, and plasma insulin. 
Microvascular improvement was associated with decreases in weight, hip 
circumference, waist circumference, HbA1C, Hs CRP, creatinine, triglycerides, 
glucose, plasma insulin, HOMA-IR, and BMI. Long term data collection will be 
required to determine if the observed improvements in vascular function are 
maintained, continue to increase, or steadily decline after the one year post-
operative time point. Furthermore, analysis of cardiovascular outcomes for these 
patients will be necessary to determine absolute risk. Additional multivariable 
analyses will reveal if any particular clinical parameter is a good criterion for 
surgery selection or predictor of vascular endothelial function improvement.  
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APPENDIX 
 
Table A.1 Descriptive Statistics for Study Population – Continuous Clinical 
Variables 
 
Variable Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
1 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
Weight, lbs 276.36  
± 55.02 
262.5 
(238 - 304.6) 
175.3 - 548.6 
366, 9 
250.57  
± 50.4 
235.4  
(213.2 - 
284.6) 
164 - 411 
86, 289 
229.61  
± 52.62 
216  
(196 - 251) 
144.6 - 437.8 
158, 217 
235.84  
± 66.63 
213.3  
(191 - 274) 
124 - 486 
66, 309 
199.1  
± 48.84 
186.4  
(164 - 226) 
126 - 416.4 
133, 242 
Waist 
Circumference
, cm 
49.33  
± 7.09 
48.5  
(44 - 53.5) 
34.5 - 75 
326, 49 
47.77  
± 5.27 
47.13  
(44 - 51.38) 
38.5 - 63 
72, 303 
43.15  
± 6.96 
42.25 
 (38 - 46.63) 
30.5 - 74 
144, 231 
44.74  
± 8.35 
43.5  
(39 - 49.5) 
30.5 - 73.5 
53, 322 
39.48  
± 7.14 
39  
(34 - 43) 
27 - 61.5 
123, 252 
Hip 
Circumference
, cm 
54.12  
± 5.96 
53.5  
(50 - 57) 
42 - 88 
313, 62 
52.38  
± 5.06 
52  
(48.38 - 55) 
41.5 - 66 
72, 303 
49.07  
± 6.1 
48  
(44.5 - 52) 
39.5 - 76 
139, 236 
50.08  
± 6.85 
49.5  
(44.5 - 54) 
39.5 - 75 
47, 328 
45.6  
± 6.05 
44.5  
(41 - 49) 
34.5 - 63 
114, 261 
Systolic BP, 
mmHg 
130.8  
± 13.99 
129.5  
(121 - 138) 
104 - 200 
276, 99 
124.71  
± 15.04 
123  
(114 - 135) 
98 - 163 
86, 289 
127.79  
± 16.5 
126  
(116.5 - 
137.5) 
82 - 185 
140, 235 
127.03  
± 16.64 
128  
(114 - 137) 
97 - 179 
67, 308 
126.46  
± 18.2 
125  
(113 - 137) 
86 - 198 
128, 247 
Diastolic BP, 
mmHg 
74.12  
± 10.52 
73  
(67 - 80) 
49 - 117 
276, 99 
72.01  
± 10.33 
69  
(65 - 78) 
47 - 99 
86, 289 
73.06  
± 10.11 
72  
(67 - 79) 
52 - 107 
140, 235 
72.07  
± 9.97 
70  
(65 - 79) 
56 - 103 
67, 308 
73.7  
± 10.33 
71.5  
(67 - 80) 
56 - 112 
128, 247 
 
 
 
 
 60 
Variable Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
1 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
Cholesterol, 
total, mg/dl 
187.4  
± 38.71 
181.5  
(160 - 209) 
91 - 354 
358, 17 
171.63  
± 38.17 
168  
(145 - 196) 
107 - 270 
75, 300 
167.71  
± 35.87 
162.5  
(144 - 191) 
79 - 283 
156, 219 
176.17  
± 31.34 
175  
(155 - 187) 
110 - 277 
63, 312 
168.48  
± 32.4 
166 
(148 - 182) 
102 - 285 
129, 246 
HDL, mg/dl 46.61  
± 13.6 
44.5  
(39 - 52) 
25 - 165 
358, 17 
38.52  
± 8.04 
38  
(33 - 42) 
24 - 68 
75, 300 
42.23  
± 12.38 
41  
(36 - 46) 
18 - 149 
157, 218 
47.16  
± 12.88 
46  
(40 - 51) 
29 - 113 
63, 312 
52.69  
± 11.69 
51  
(45 - 60) 
23 - 107 
129, 246 
LDL, mg/dl 115.17  
± 33.54 
112.5  
(93 - 135) 
10 - 292 
356, 19 
111.64  
± 32.37 
105  
(90 - 134) 
51 - 192 
75, 300 
105.72  
± 30.09 
103  
(83.5 - 124) 
33 - 212 
156, 219 
108.55  
± 26.41 
108.5  
(90 - 119) 
59 - 182 
62, 313 
98.71  
± 27.56 
98  
(81 - 113) 
32 - 201 
129, 246 
Triglycerides, 
mg/dl 
129.09  
± 74.93 
109  
(79 - 161) 
31 - 548 
356, 19 
107.23  
± 37.36 
99  
(77 - 126) 
45 - 207 
75, 300 
100.4  
± 39.45 
91.5  
(72 - 119) 
43 - 238 
156, 219 
100.66  
± 41.41 
93  
(67 - 130) 
43 - 253 
62, 313 
86.29  
± 38.95 
77  
(62 - 102) 
29 - 240 
129, 246 
Glucose, 
mg/dl 
113.33  
± 54.26 
96  
(87 - 114) 
14 - 429 
358, 17 
97.85  
± 23.02 
93  
(85 - 103) 
69 - 213 
74, 301 
98.63  
± 33.25 
89 
(82 - 99.5) 
64 - 294 
156, 219 
95.38  
± 23.2 
89  
(82 - 102) 
66 - 210 
63, 312 
93.85  
± 28.4 
88  
(81 - 94) 
62 - 324 
129, 246 
Plasma 
Insulin, µIU/ml 
15.09  
± 8.3 
13.5  
(9 - 19) 
0.2 - 50 
336, 39 
7.92  
± 6.35 
6  
(3 - 10) 
2 - 31 
72, 303 
8.19  
± 5.62 
7  
(4 - 10) 
2 - 42 
149, 226 
7.26  
± 6.27 
5.5  
(3 - 9) 
2 - 33 
58, 317 
6.3  
± 4.93 
5  
(4 - 7) 
2 - 34 
128, 247 
HbA1C, % 6.26  
± 1.66 
5.8  
(5.4 - 6.4) 
4.2 - 15.4 
349, 26 
5.76  
± 0.99 
5.45  
(5.2 - 6) 
4.8 - 10.7 
74, 301 
5.71  
± 0.97 
5.5  
(5.2 - 5.9) 
3.9 - 9.7 
152, 223 
5.59  
± 0.75 
5.5  
(5.3 - 5.7) 
4.5 - 9.1 
61, 314 
5.56  
± 0.91 
5.4  
(5.1 - 5.7) 
4.3 - 9.5 
126, 249 
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Variable Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
1 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
Hs CRP, mg/dl 9.86  
± 9.93 
7  
(3.5 - 13.4) 
0.2 - 88.9 
290, 85 
6.58  
± 8.22 
3  
(1.3 - 6.8) 
0.2 - 33.3 
57, 318 
7.06  
± 8.35 
4.1  
(1.7 - 8.25) 
0.2 - 53 
128, 247 
4.04  
± 5.62 
2.15  
(1.1 - 4.45) 
0.2 - 27.1 
44, 331 
3.41  
± 6.75 
1.3  
(0.5 - 3.2) 
0.1 - 54.6 
106, 269 
CRP, mg/dl 1.88  
± 2.38 
1.2  
(0.7 - 2.2) 
0.2 - 16.9 
63, 312 
0.94  
± 0.97 
0.6  
(0.3 - 1.2) 
0.1 - 3.8 
17, 358 
1.66  
± 2.15 
0.6  
(0.3 - 2.2) 
0.1 - 7.9 
14, 361 
1.06  
± 1.51 
0.2  
(0.2 - 1.1) 
0.1 - 4.2 
9, 366 
0.38  
± 0.48 
0.1  
(0.1 - 0.5) 
0.1 - 1.5 
13, 362 
Creatinine, 
mg/dl 
0.81  
± 0.23 
0.76  
(0.69 - 0.85) 
0.37 - 2.75 
357, 18 
0.75  
± 0.14 
0.74  
(0.64 - 0.8) 
0.5 - 1.13 
74, 301 
0.74  
± 0.19 
0.7  
(0.63 - 0.8) 
0.47 - 2.2 
155, 220 
0.69  
± 0.13 
0.68  
(0.6 - 0.77) 
0.4 - 1.01 
64, 311 
0.73  
± 0.2 
0.7  
(0.64 - 0.79) 
0.4 - 2.31 
127, 248 
Urine 
Creatinine, 
mg/dl 
1542.22  
± 880.56 
1411.9 
(955.9 - 
1929) 
0.66 - 4930 
231, 144 
2825.25  
± 1386.19 
2852  
(1882 - 3702) 
142 - 6081 
77, 298 
2278.27  
± 1124.39 
2515  
(1515 - 3030) 
0.47 - 4827 
87, 288 
1944.9  
± 1371.21 
1668  
(1022 - 
2616) 
216 - 7194 
63, 312 
1392.97  
± 734.02 
1248  
(851 - 1779) 
163 - 3416 
71, 304 
BMI, kg/m2 45.59  
± 8.11 
43.59  
(40.38 - 
48.85) 
32.19 - 98.32 
366, 9 
41.64  
± 7.3 
40.66  
(37 - 44.77) 
29.44 - 68.39 
86, 289 
37.56  
± 7.93 
35.47  
(32.3 - 40.9) 
25.39 - 72.85 
158, 217 
38.46  
± 10.01 
36.54  
(31.2 - 
43.09) 
22.68 - 
80.87 
66, 309 
32.82  
± 7.61 
30.95 
(27.54 - 
35.96) 
20.59 - 
69.29 
133, 242 
HOMA-IR 4.19  
± 3.27 
3.24  
(2.24 - 5.12) 
0.04 - 26.46 
330, 45 
2  
± 1.8 
1.5  
(0.64 - 2.6) 
0.38 - 9.56 
70, 305 
2.04  
± 1.92 
1.5  
(0.94 - 2.58) 
0.39 - 16.16 
147, 228 
1.77  
± 1.69 
1.29  
(0.65 - 1.84) 
0.37 - 8.14 
57, 318 
1.47  
± 1.26 
1.09  
(0.78 - 1.62) 
0.37 - 8.47 
126, 249 
IQR is interquartile range, N is the number of patients included in analysis for the 
parameter, and N Missing is the number of patients from the total study population not 
included in analysis for the parameter. 
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Table A.2 Differences from Baseline by Follow-up Visit – Continuous Clinical 
Variables 
 
Variable 1 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Weight, lbs -28.42  
± 10.91 
-29.2  
(-33.7 - -21) 
-59.4 - 7.2 
86, 289 
-47.83  
± 17.11 
-48.9  
(-57.6 - -38.4) 
-94.6 - 9.8 
158, 217 
-66.58  
± 31.69 
-68.5  
(-88.6 - -51.76) 
-131 - 54 
66, 309 
-82.07 ± 33.98 
-76.8  
(-100.2 - -
60.4) 
-202.8 - -1.6 
133, 242 
Waist 
Circumference, 
cm 
-3.22  
± 1.98 
-3.25  
(-4.5 - -2) 
-7.5 - 2.4 
71, 304 
-6.44  
± 3.01 
-6.5  
(-8 - -5) 
-17 - 2 
140, 235 
-8.82  
± 4.06 
-9  
(-11.75 - -6) 
-18.25 - 1.5 
49, 326 
-10.74  
± 4.96 
-10.25  
(-14.88 - -7.5) 
-23 - 0 
116, 259 
Hip 
Circumference, 
cm 
-2.41  
± 1.82 
-2.5  
(-3.5 - -1) 
-6.75 - 4 
69, 306 
-5.04  
± 2.6 
-5.5  
(-6.5 - -3.88) 
-12 - 4.5 
136, 239 
-6.88  
± 3.24 
-7  
(-9.5 - -5.38) 
-12.5 - 3.5 
44, 331 
-9.66  
± 4.77 
-8.75  
(-12.38 - -6.38) 
-27 - 3 
108, 267 
Systolic BP, mm 
Hg 
-6.6  
± 16.22 
-7.5  
(-14 - 3) 
-73 - 25 
86, 289 
-4.07  
± 17.7 
-4  
(-15 - 7) 
-58 - 52 
129, 246 
-5.34  
± 19.86 
-6  
(-19 - 9) 
-66 - 33 
67, 308 
-3.82  
± 18.76 
-4  
(-14 - 7) 
-64 - 52 
105, 270 
Diastolic BP, mm 
Hg 
-0.76  
± 10.04 
-0.5  
(-6 - 5) 
-32 - 26 
86, 289 
-1.05  
± 10.45 
-2  
(-8 - 5) 
-24 - 24 
129, 246 
-0.42  
± 10.78 
0  
(-8 - 5) 
-25 - 26 
67, 308 
0.6  
± 10.52 
0  
(-7 - 8) 
-19 - 35 
105, 270 
Cholesterol, 
total, mg/dl 
-15.68  
± 35.03 
-20  
(-43 - 5) 
-92 - 75 
75, 300 
-17.03  
± 37.14 
-19  
(-40 - 4) 
-146 - 70 
154, 221 
-12.66  
± 32.36 
-13.5  
(-28 - 7) 
-89 - 67 
62, 313 
-13.9  
± 35.07 
-15  
(-36 - 7) 
-126 - 100 
127, 248 
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Variable 1 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
HDL, mg/dl -8.17  
± 6.72 
-7  
(-12 - -4) 
-26 - 4 
75, 300 
-3.32  
± 11.08 
-3  
(-8 - 1) 
-28 - 103 
155, 220 
-0.08  
± 18.56 
1  
(-4 - 5) 
-122 - 54 
62, 313 
6.11  
± 14.23 
6  
(0 - 13) 
-114 - 50 
127, 248 
LDL, mg/dl -4.76  
± 30.67 
-12  
(-28 - 13) 
-70 - 99 
75, 300 
-7.71  
± 33.2 
-13  
(-30 - 6) 
-101 - 91 
153, 222 
-7.02  
± 30.8 
-3  
(-20 - 8) 
-86 - 59 
61, 314 
-12.67  
± 32.48 
-14  
(-33 - 6) 
-82 - 96 
126, 249 
Triglycerides, 
mg/dl 
-16.36  
± 51.32 
-4  
(-40 - 12) 
-168 - 71 
74, 301 
-27.31  
± 63.63 
-18  
(-39 - 1) 
-405 - 120 
154, 221 
-38.02  
± 59.25 
-22  
(-65 - -1) 
-255 - 60 
61, 314 
-34.29  
± 56.44 
-27  
(-68 - 2) 
-253 - 94 
126, 249 
Glucose, mg/dl -10.85  
± 22.76 
-10  
(-22 - 3) 
-74 - 48 
73, 302 
-22.64  
± 57.38 
-8.5  
(-23 - -2) 
-276 - 120 
154, 221 
-17.48  
± 31.7 
-8.5  
(-26 - -2) 
-177 - 55 
62, 313 
-25.26  
± 55.86 
-9.5  
(-27 - -3) 
-330 - 70 
128, 247 
Plasma Insulin, 
µIU/ml 
-5.43  
± 6.63 
-6  
(-9 - -2) 
-23 - 17 
70, 305 
-7.65  
± 7.31 
-7  
(-11 - -3) 
-37 - 12 
142, 233 
-8.4  
± 7.8 
-7  
(-14 - -3) 
-30 - 13 
55, 320 
-8.48  
± 7.35 
-7.5  
(-12.5 - -4) 
-29 - 14 
120, 255 
HbA1C, % -0.59  
± 0.76 
-0.4  
(-0.8 - -0.2) 
-4.7 - 0.3 
74, 301 
-0.78  
± 1.32 
-0.4  
(-0.8 - -0.2) 
-8.7 - 0.4 
149, 226 
-0.69  
± 0.73 
-0.5  
(-0.9 - -0.2) 
-2.9 - 0.2 
58, 317 
-0.83  
± 1.24 
-0.5  
(-1 - -0.2) 
-8.2 - 0.8 
120, 255 
Hs CRP, mg/dl -3.29  
± 11.68 
-1.3  
(-2.9 - -0.1) 
-72.8 - 17.5 
51, 324 
-3.63  
± 8.76 
-3.1  
(-8.6 - -0.8) 
-21.6 - 43.9 
122, 253 
-5.64  
± 6.19 
-3.55  
(-7.65 - -2.1) 
-24.8 - 1.8 
36, 339 
-6.67  
± 7.76 
-5.2  
(-11 - -2.1) 
-37.8 - 21.8 
95, 280 
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Variable 1 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
CRP, mg/dl -0.48  
± 0.98 
-0.6  
(-1 - 0.2) 
-2.4 - 1 
13, 362 
-1.48  
± 1.93 
-1  
(-1.75 - -0.25) 
-5.9 - 0.1 
8, 367 
-0.62  
± 0.82 
-0.4  
(-0.6 - -0.3) 
-2.2 - 0.2 
6, 369 
-0.5  
± 0.14 
-0.4  
(-0.6 - -0.4) 
-0.7 - -0.4 
5, 370 
Creatinine, mg/dl -0.03  
± 0.1 
-0.01  
(-0.1 - 0.03) 
-0.24 - 0.21 
72, 303 
-0.1  
± 0.16 
-0.07  
(-0.15 - -0.01) 
-1.18 - 0.22 
152, 223 
-0.07  
± 0.11 
-0.07  
(-0.15 - 0.02) 
-0.3 - 0.2 
63, 312 
-0.07  
± 0.12 
-0.05  
(-0.13 - 0) 
-0.46 - 0.33 
122, 253 
Urine Creatinine, 
mg/dl 
1302.28  
± 1535.63 
1343  
(139 - 2374) 
-3080 - 4391 
75, 300 
686.86  
± 1284.62 
751.5  
(-117.2 - 
1623) 
-3044 - 3986 
78, 297 
227.63  
± 1413.84 
270  
(-547.35 - 846) 
-3254.2 - 3959 
60, 315 
-173.43  
± 1036.91 
-29  
(-831 - 360) 
-3019.1 - 1982 
63, 312 
BMI, kg/m2 -4.72  
± 1.71 
-4.67  
(-5.78 - -3.66) 
-8.75 - 1.2 
86, 289 
-7.8  
± 2.62 
-7.96  
(-9.41 - -6.49) 
-14.72 - 1.63 
158, 217 
-10.92  
± 5.06 
-11.9  
(-14.33 - -8.52) 
-19.5 - 8.99 
66, 309 
-13.5  
± 5.36 
-12.98  
(-16.21 - -
10.03) 
-32.37 - -0.28 
133, 242 
HOMA-IR -1.64  
± 2.02 
-1.6  
(-2.62 - -0.5) 
-7.33 - 6.48 
67, 308 
-2.72  
± 3.15 
-1.86  
(-3.6 - -1.01) 
-16.63 - 2.98 
138, 237 
-2.54  
± 2.53 
-1.94  
(-4 - -0.93) 
-9.04 - 3.43 
53, 322 
-2.8  
± 2.65 
-2.07  
(-3.88 - -1.01) 
-12.03 - 2.66 
117, 258 
IQR is interquartile range, N is the number of patients included in analysis for the 
parameter, and N Missing is the number of patients from the total study population not 
included in analysis for the parameter. 
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Table A.3. Descriptive Statistics Stratified by Baseline Plasma Insulin Level, by 
Visit – Continuous Clinical Variables 
 
Variable Baseline 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
1 mo. 
Follow-
up  
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
Weight, lbs Low 
 
267.37 ± 
48.08 
254.4 
(233.1 - 
293) 
175.3 - 
456 
168, 0 
244.5 ± 
46.88 
232.7 
(211.6 - 
265.4) 
164 - 
385.4 
62, 0 
223.13 ± 
43.81 
212.55 
(194.8 - 
241.9) 
144.6 - 
371.6 
128, 0 
220.33 ± 
52.97 
201.2 
(179.2 - 
248) 
124 - 355 
49, 1 
195.52 ± 
45.55 
182.6 
(163 - 
222.6) 
126 - 
345.8 
117, 2 
 High 285.58 ± 
61.68 
271.9 
(242.45 - 
315.5) 
184.4 - 
548.6 
168, 0 
255.44 ± 
41.76 
256.99 
(214 - 
266.6) 
209.6 - 
344.4 
10, 0 
258.54 ± 
75.31 
229.6 
(210.6 - 
285) 
156.4 - 
428.2 
21, 0 
297.98 ± 
67.63 
299.4 
(245.3 - 
334.7) 
206.4 - 
418.6 
8, 0 
219.62 ± 
44.44 
223.4 
(198 - 
237.4) 
155.4 - 
310 
9, 0 
Waist 
Circumference, 
cm 
Low 
 
47.71 ± 
6.19 
46.5 (44 - 
51.5) 
34.5 - 67 
157, 11 
47.51 ± 
5.24 
47 (44 - 
50.63) 
38.5 - 63 
60, 2 
42.41 ± 
6.06 
42 (38 - 
45) 
30.5 - 60 
120, 8 
43 ± 6.47 
43 (38.25 
- 45) 
30.5 - 58 
45, 5 
39.24 ± 
7.09 
38 (33.75 
- 43) 
28 - 61.5 
112, 7 
 High 50.89 ± 
7.96 
50 (45 - 
55) 
36.75 - 75 
142, 26 
49 ± 5.8 
50 (45 - 
52) 
40.5 - 60 
10, 0 
47.22 ± 
10.61 
46.25 (39 
- 52) 
34 - 74 
19, 2 
56.75 ± 
10.89 
53.75 (48 
- 66) 
45.5 - 
73.5 
6, 2 
43.33 ± 
7.57 
39.75 
(39.5 - 
45) 
38 - 58 
6, 3 
Hip 
Circumference, 
cm 
Low 53.97 ± 
5.2 
53.88 (50 
- 57) 
44 - 72 
152, 16 
52.11 ± 
4.85 
52 (48.38 
- 55) 
41.5 - 63 
60, 2 
48.49 ± 
5.42 
47.7 (44.5 
- 52) 
39.5 - 63.5 
118, 10 
48.83 ± 
5.16 
48.38 
(44.5 - 52) 
39.5 - 
59.5 
40, 10 
45.39 ± 
6.02 
44.5 (41 - 
49) 
34.5 - 63 
103, 16 
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
1 mo. 
Follow-
up  
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
 High 54.47 ± 
6.81 
53.5 (50 - 
57.5) 
43.5 - 88 
135, 33 
53.88 ± 
6.23 
54.5 
(49.25 - 
57) 
45.5 - 66 
10, 0 
51.92 ± 
8.98 
49.75 (48 
- 58) 
40 - 76 
18, 3 
59.46 ± 
9.92 
56.5 
(53.75 - 
67) 
48 - 75 
6, 2 
48.92 ± 
7.31 
49.75 (42 
- 52) 
40 - 60 
6, 3 
Systolic BP, 
mmHg 
Low 131.45 ± 
13.99 
130.5 
(122 - 
138) 
106 - 200 
128, 40 
124.68 ± 
14.5 
123 (115 
- 136) 
98 - 162 
62, 0 
128.8 ± 
17.67 
126 (117 - 
139) 
82 - 185 
109, 19 
126.34 ± 
15.15 
129.5 
(113 - 
138) 
97 - 152 
50, 0 
126.36 ± 
18.73 
124.5 
(112.5 - 
137) 
86 - 198 
112, 7 
 High 130.4 ± 
14.04 
129 (120 - 
139) 
104 - 196 
130, 38 
131.5 ± 
17.83 
129 (119 
- 143) 
105 - 163 
10, 0 
124.86 ± 
10.67 
127 (120 - 
131) 
101 - 142 
21, 0 
130 ± 
20.65 
126 (119 - 
129) 
113 - 179 
8, 0 
124.78 ± 
11.9 
125 (116 
- 135) 
107 - 140 
9, 0 
Diastolic BP, 
mmHg 
Low 75.18 ± 
9.76 
74 (68 - 
81) 
56 - 117 
128, 40 
72.39 ± 
10.54 
69 (65 - 
79) 
47 - 96 
62, 0 
73.87 ± 
10.3 
73 (67 - 
81) 
52 - 107 
109, 19 
71.84 ± 
8.97 
69 (66 - 
78) 
56 - 90 
50, 0 
73.95 ± 
10.63 
72.5 (67 - 
80.5) 
56 - 112 
112, 7 
 High 73.5 ± 
11.4 
73 (67 - 
80) 
49 - 113 
130, 38 
73.9 ± 
11.42 
70 (68 - 
78) 
58 - 99 
10, 0 
70.43 ± 
8.48 
69 (65 - 
75) 
55 - 88 
21, 0 
74.5 ± 
13.98 
69 (65.5 - 
82) 
60 - 103 
8, 0 
70.78 ± 
7.17 
69 (67 - 
70) 
62 - 85 
9, 0 
Cholesterol, 
total, mg/dl 
Low 188.2 ± 
37.36 
184 
(159.5 - 
212) 
91 - 306 
168, 0 
168.71 ± 
34.57 
167.5 
(147 - 
192) 
107 - 270 
62, 0 
165.24 ± 
33.17 
162 (144 - 
187) 
79 - 280 
128, 0 
170.86 ± 
27.82 
170 (153 - 
185) 
110 - 277 
50, 0 
165.92 ± 
27.6 
165 (148 
- 182) 
102 - 262 
116, 3 
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
1 mo. 
Follow-
up  
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
 High 184.94 ± 
37.24 
180 (160 - 
202) 
108 - 354 
167, 1 
187.9 ± 
48.61 
185.5 
(141 - 
241) 
126 - 260 
10, 0 
170.16 ± 
43.88 
175 (130 - 
194) 
117 - 255 
19, 2 
204.75 ± 
44.84 
202.5 
(173 - 
245.5) 
135 - 261 
8, 0 
197.11 ± 
65.84 
180 (149 
- 261) 
103 - 285 
9, 0 
HDL, mg/dl Low 48.77 ± 
11.7 
47 (41 - 
54) 
28 - 97 
168, 0 
38.31 ± 
8.14 
37.5 (33 
- 41) 
24 - 68 
62, 0 
41.79 ± 
12.98 
40 (35 - 
45.5) 
18 - 149 
128, 0 
46.5 ± 
10.28 
46 (40 - 
50) 
29 - 83 
50, 0 
53.01 ± 
11.75 
51 (45 - 
61) 
23 - 107 
116, 3 
 High 43.88 ± 
12.22 
43 (38 - 
49) 
25 - 157 
167, 1 
38.9 ± 
7.95 
37.5 (34 
- 42) 
28 - 57 
10, 0 
42.85 ± 
8.76 
41.5 (36 - 
50) 
29 - 57 
20, 1 
45.88 ± 
8.06 
44.5 (39 - 
52.5) 
37 - 58 
8, 0 
50.22 ± 
10.18 
53 (48 - 
55) 
33 - 68 
9, 0 
LDL, mg/dl Low 117.24 ± 
32.5 
117 (93 - 
141) 
10 - 200 
167, 1 
110 ± 
30.42 
105 (91 - 
131) 
51 - 192 
62, 0 
104.74 ± 
28.58 
103 (85 - 
120) 
33 - 212 
127, 1 
105.54 ± 
23.37 
107.5 (90 
- 118) 
59 - 182 
50, 0 
96.41 ± 
24.16 
96 (81.5 - 
111.5) 
32 - 184 
116, 3 
 High 113.94 ± 
32.95 
111 (94 - 
129) 
30 - 292 
167, 1 
123.1 ± 
38.12 
115 (92 - 
166) 
81 - 177 
10, 0 
103.5 ± 
32.97 
87.5 (78 - 
126.5) 
60 - 171 
20, 1 
133 ± 
35.84 
139 
(110.5 - 
162) 
70 - 171 
8, 0 
122.44 ± 
52.26 
109 (78 - 
171) 
59 - 201 
9, 0 
Triglycerides, 
mg/dl 
Low 109.49 ± 
60.23 
94 (69.5 - 
131) 
31 - 375 
168, 0 
101.97 ± 
33.86 
97.5 (76 
- 117) 
45 - 207 
62, 0 
96.77 ± 
37.5 
90 (71 - 
115) 
43 - 238 
127, 1 
94.24 ± 
40.81 
84 (64 - 
117) 
43 - 253 
50, 0 
83.51 ± 
37.59 
76 (59 - 
100) 
29 - 240 
116, 3 
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
1 mo. 
Follow-
up  
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
 High 135.16 ± 
66.78 
119 (90 - 
166) 
39 - 447 
166, 2 
128.8 ± 
39.67 
131 (90 - 
164) 
70 - 185 
10, 0 
109.6 ± 
49.57 
93.5 (75 - 
115) 
67 - 234 
20, 1 
129.5 ± 
40.04 
135.5 
(99.5 - 
156.5) 
67 - 186 
8, 0 
122.22 ± 
46.73 
115 (89 - 
144) 
57 - 194 
9, 0 
Glucose, mg/dl Low 105.01 ± 
46.4 
92 (84 - 
105) 
14 - 407 
165, 3 
96.58 ± 
23.58 
89 (84.5 
- 102) 
69 - 213 
60, 2 
95.73 ± 
30.61 
87 (82 - 
98) 
64 - 294 
127, 1 
93.55 ± 
23.86 
87 (82 - 
94) 
66 - 210 
49, 1 
93.65 ± 
28.99 
88 (81 - 
94) 
62 - 324 
117, 2 
 High 116.49 ± 
53.68 
101 (90 - 
117) 
62 - 429 
165, 3 
110.4 ± 
19.07 
106 (96 - 
129) 
84 - 137 
10, 0 
102.2 ± 
25.77 
92.5 (88 - 
102.5) 
80 - 169 
20, 1 
109.13 ± 
22.54 
103 (92 - 
124) 
84 - 151 
8, 0 
98.22 ± 
26.09 
93 (87 - 
101) 
73 - 162 
9, 0 
Plasma Insulin, 
µIU/ml 
Low 8.98 ± 
3.17 
9 (7 - 12) 
0.2 - 13 
168, 0 
5.85 ± 
3.28 
6 (3 - 8) 
2 - 13 
62, 0 
6.49 ± 
3.14 
6 (4 - 9) 
2 - 13 
128, 0 
5.14 ± 
2.78 
4.5 (3 - 7) 
2 - 11 
50, 0 
5.26 ± 
2.59 
5 (3 - 7) 
2 - 13 
119, 0 
 High 21.19 ± 
7.3 
19 (16 - 
24) 
14 - 50 
168, 0 
20.7 ± 
5.83 
21 (15 - 
24) 
14 - 31 
10, 0 
18.57 ± 
6.26 
17 (15 - 
21) 
14 - 42 
21, 0 
20.5 ± 
5.76 
19 (16.5 - 
22.5) 
15 - 33 
8, 0 
20 ± 7.7 
15 (15 - 
23) 
14 - 34 
9, 0 
HbA1C, % Low 6.05 ± 
1.42 
5.6 (5.3 - 
6.1) 
4.2 - 12.7 
165, 3 
5.79 ± 1 
5.5 (5.2 - 
6.1) 
4.8 - 10.7 
62, 0 
5.59 ± 
0.83 
5.4 (5.1 - 
5.8) 
3.9 - 8.8 
123, 5 
5.58 ± 0.8 
5.5 (5.3 - 
5.7) 
4.5 - 9.1 
49, 1 
5.51 ± 
0.84 
5.4 (5.1 - 
5.6) 
4.3 - 9.5 
113, 6 
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
1 mo. 
Follow-
up  
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
 High 6.32 ± 
1.71 
5.9 (5.4 - 
6.5) 
4.2 - 15.4 
163, 5 
5.78 ± 
0.98 
5.65 (5.3 
- 5.9) 
4.8 - 8.3 
10, 0 
6.01 ± 
1.31 
5.65 (5.15 
- 6.35) 
4.8 - 9.7 
20, 1 
5.81 ± 0.6 
5.9 (5.45 - 
6.3) 
4.7 - 6.5 
8, 0 
6.39 ± 
1.44 
5.9 (5.5 - 
6.7) 
4.7 - 9.3 
9, 0 
HsCRP, mg/dl Low 9.39 ± 
11.27 
6 (3.1 - 
9.9) 
0.2 - 88.9 
147, 21 
6.59 ± 
8.48 
2.9 (1.3 - 
6.8) 
0.3 - 33.3 
47, 15 
6.89 ± 
8.56 
3.8 (1.6 - 
8.15) 
0.2 - 53 
108, 20 
3.54 ± 
5.37 
1.75 (1 - 
3.6) 
0.2 - 27.1 
38, 12 
3.28 ± 
6.73 
1.2 (0.5 - 
3.2) 
0.1 - 54.6 
99, 20 
 High 10.69 ± 
8.62 
7.6 (4.2 - 
15.5) 
0.3 - 39.1 
125, 43 
7.35 ± 
7.92 
4.9 (1.35 
- 11.25) 
0.2 - 23.6 
8, 2 
8.59 ± 
7.44 
6.25 (4.2 - 
11.4) 
0.5 - 29.1 
18, 3 
8.44 ± 
6.63 
7.8 (4.1 - 
7.9) 
2.8 - 19.6 
5, 3 
6.08 ± 
7.67 
2.2 (1.8 - 
8.8) 
0.9 - 20.6 
6, 3 
CRP, mg/dl Low 1.31 ± 0.9 
1.1 (0.65 - 
1.55) 
0.4 - 4.5 
24, 144 
0.87 ± 
0.92 
0.6 (0.2 - 
1.2) 
0.1 - 3.8 
15, 47 
1.55 ± 
2.35 
0.6 (0.3 - 
1.8) 
0.1 - 7.9 
10, 118 
0.73 ± 
1.06 
0.2 (0.1 - 
1.1) 
0.1 - 3 
7, 43 
0.41 ± 
0.49 
0.15 (0.1 
- 0.5) 
0.1 - 1.5 
12, 107 
 High 2.14 ± 
2.82 
1.2 (0.8 - 
2.6) 
0.2 - 16.9 
37, 131 
1.45 ± 
1.63 
1.45 (0.3 
- 2.6) 
0.3 - 2.6 
2, 8 
2.25 ± 
2.47 
2.25 (0.5 - 
4) 
0.5 - 4 
2, 19 
2.2 ± 2.83 
2.2 (0.2 - 
4.2) 
0.2 - 4.2 
2, 6 
0.1 ± . 
0.1 (0.1 - 
0.1) 
0.1 - 0.1 
1, 8 
Creatinine, 
mg/dl 
Low 0.79 ± 
0.19 
0.75 (0.69 
- 0.85) 
0.5 - 1.93 
166, 2 
0.75 ± 
0.14 
0.74 
(0.65 - 
0.81) 
0.5 - 1.13 
60, 2 
0.74 ± 0.2 
0.7 (0.63 - 
0.82) 
0.47 - 2.2 
127, 1 
0.7 ± 0.13 
0.69 (0.6 - 
0.77) 
0.4 - 1.01 
50, 0 
0.74 ± 
0.2 
0.7 (0.65 
- 0.8) 
0.4 - 2.31 
115, 4 
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
1 mo. 
Follow-
up  
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
 High 0.81 ± 
0.27 
0.76 (0.69 
- 0.83) 
0.37 - 
2.75 
163, 5 
0.76 ± 
0.18 
0.73 
(0.61 - 
0.81) 
0.55 - 
1.12 
10, 0 
0.72 ± 
0.13 
0.69 (0.65 
- 0.78) 
0.5 - 1.01 
20, 1 
0.73 ± 
0.13 
0.69 (0.62 
- 0.85) 
0.6 - 0.93 
8, 0 
0.68 ± 
0.1 
0.68 (0.6 
- 0.78) 
0.52 - 0.8 
8, 1 
Urine 
Creatinine, 
mg/dl 
Low 1575.47 ± 
954.26 
1382.45 
(922 - 
1924) 
113 - 
4930 
112, 56 
2957.52 
± 
1420.28 
2908 
(1882 - 
4003) 
157 - 
6081 
59, 3 
2294.08 ± 
1185.85 
2533.5 
(1516.85 - 
3004.2) 
0.47 - 
4827 
68, 60 
1986.48 ± 
1433.45 
1778 
(1073 - 
2584) 
216 - 
7194 
49, 1 
1394.29 
± 740.43 
1251 
(851 - 
1779) 
163 - 
3416 
67, 52 
 High 1557.51 ± 
817.42 
1442 
(968.2 - 
2089) 
1.12 - 
4447 
105, 63 
2397 ± 
1308.44 
2009 
(1455 - 
3194) 
965 - 
4895 
8, 2 
2243.45 ± 
911.1 
2428.5 
(1668 - 
2986) 
321 - 
3362.4 
12, 9 
2236.99 ± 
1203.76 
1874.5 
(1441.95 - 
2645) 
1111 - 
4862 
8, 0 
1015.85 
± 253.36 
1015.85 
(836.7 - 
1195) 
836.7 - 
1195 
2, 7 
BMI, kg/m2 Low 44.39 ± 
6.37 
43.33 
(40.13 - 
47.41) 
32.19 - 
71.87 
168, 0 
40.63 ± 
6.33 
40.19 (37 
- 42.7) 
29.44 - 
68.03 
62, 0 
36.36 ± 
6.15 
35.15 
(32.25 - 
39.45) 
25.39 - 
59.21 
128, 0 
36.01 ± 
7.03 
34.41 
(31.18 - 
41.26) 
22.68 - 
54.45 
49, 1 
32.21 ± 
6.92 
30.4 
(27.14 - 
35.54) 
20.59 - 
55.78 
117, 2 
 High 47.05 ± 
9.59 
44.06 
(40.59 - 
51.55) 
33.17 - 
98.32 
168, 0 
44.32 ± 
7.74 
44.44 
(36.52 - 
48.76) 
33.83 - 
55.58 
10, 0 
42.93 ± 
11.88 
41.15 
(34.81 - 
46.03) 
28.25 - 
71.25 
21, 0 
48.62 ± 
10.63 
45.42 
(40.95 - 
54.21) 
38.16 - 
69.65 
8, 0 
36.64 ± 
7.71 
35.15 
(32.95 - 
39.45) 
26.67 - 
53.21 
9, 0 
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Variable Baseline 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
1 mo. 
Follow-
up  
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
HOMA-IR Low 2.27 ± 
1.14 
2.24 (1.66 
- 2.69) 
0.04 - 
10.18 
165, 3 
1.4 ± 
0.82 
1.3 (0.61 
- 2.07) 
0.38 - 
3.24 
60, 2 
1.59 ± 
1.13 
1.35 (0.86 
- 2.12) 
0.39 - 8.7 
127, 1 
1.17 ± 
0.63 
1.09 (0.61 
- 1.54) 
0.37 - 2.9 
49, 1 
1.21 ± 
0.68 
1.05 
(0.76 - 
1.58) 
0.37 - 
4.07 
117, 2 
 High 6.12 ± 
3.57 
4.98 (3.73 
- 7.08) 
2.41 - 
26.46 
165, 3 
5.61 ± 
1.87 
4.82 
(4.22 - 
6.39) 
3.49 - 
9.56 
10, 0 
4.88 ± 
3.13 
3.71 (3.36 
- 4.9) 
2.76 - 
16.16 
20, 1 
5.44 ± 
1.49 
5.5 (4.17 - 
6.19) 
3.63 - 
8.14 
8, 0 
4.84 ± 
2.1 
3.61 
(3.25 - 
6.01) 
2.7 - 8.47 
9, 0 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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Tables A.4. Differences from Baseline Stratified by Baseline Plasma Insulin Level, 
by Follow-up Visit – Continuous Clinical Variables 
Variable Baseline 
Insulin 
Status 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
1 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
6 mo. 
Follow up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N 
Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Weight, lbs Low -29 ± 9.93 
-29.7 (-33.7 
- -22.2) 
-59.4 - -9.6 
62, 0 
-49.19 ± 
14.72 
-50 (-57.1 - 
-39.3) 
-94.6 - 2 
128, 0 
-71.39 ± 
24.16 
-69.24 (-
88.6 - -56) 
-131 - -6.6 
49, 1 
-83.6 ± 
33.32 
-77.8 (-
100.2 - -
63.2) 
-202.8 - -1.6 
117, 2 
 High -26.41 ± 
9.64 
-22.5 (-33.4 
- -20.3) 
-43 - -16 
10, 0 
-39.16 ± 
21.23 
-41.2 (-50.4 
- -29.6) 
-78.1 - 9.8 
21, 0 
-47.94 ± 
43.51 
-49.5 (-75.3 
- -13.85) 
-117.2 - 11 
8, 0 
-67.81 ± 
39.29 
-59.6 (-75 - -
46) 
-135 - -19.6 
9, 0 
Waist 
Circumference, 
cm 
Low 
 
-3.27 ± 
1.99 
-3.38 (-4.25 
- -2.25) 
-7.5 - 2.4 
60, 2 
-6.68 ± 
2.89 
-7 (-8 - -5) 
-17 - 1.65 
120, 8 
-9.18 ± 3.77 
-9.63 (-12 - 
-6) 
-18.25 - -
2.71 
42, 8 
-10.83 ± 
5.07 
-10.5 (-15 - -
7.5) 
-23 - 0 
106, 13 
 High -3.25 ± 
2.04 
-3 (-5 - -2) 
-5.5 - 0 
9, 1 
-5.04 ± 
3.23 
-5.5 (-7 - -
3) 
-11 - 2 
18, 3 
-5.3 ± 5.65 
-8 (-9 - 0) 
-11 - 1.5 
5, 3 
-8.85 ± 4.39 
-8 (-10.5 - -
6) 
-15.5 - -4.25 
5, 4 
Hip 
Circumference, 
cm 
Low 
 
-2.45 ± 
1.92 
-3 (-3.75 - -
1) 
-6.75 - 4 
58, 4 
-5.31 ± 2.4 
-5.5 (-6.5 - -
4) 
-12 - 4.5 
117, 11 
-7.28 ± 2.65 
-7 (-9.75 - -
5.5) 
-12.5 - -1 
39, 11 
-9.84 ± 4.79 
-8.88 (-12.5 
- -6.5) 
-27 - 3 
98, 21 
 High -2.19 ± 
1.29 
-2 (-2.5 - -
1.5) 
-4.75 - -0.5 
9, 1 
-3.32 ± 
3.12 
-4 (-5.5 - -
1.5) 
-8 - 4.5 
17, 4 
-2.38 ± 5.46 
-1.88 (-6.5 - 
1.75) 
-9.25 - 3.5 
4, 4 
-5.55 ± 4.13 
-6 (-7.5 - -3) 
-11 - -0.25 
5, 4 
 
 
 
 73 
Systolic BP, 
mmHg 
Low -6.13 ± 
16.28 
-7.5 (-14 - 
3) 
-73 - 25 
62, 0 
-2.02 ± 
17.21 
-4 (-13 - 8) 
-58 - 52 
101, 27 
-6.02 ± 
20.21 
-5.5 (-19 - 
8) 
-66 - 33 
50, 0 
-3.69 ± 18.7 
-3 (-17 - 7) 
-64 - 52 
91, 28 
 High -6.5 ± 20.6 
-4.5 (-12 - 
11) 
-43 - 17 
10, 0 
-10.06 ± 
18.23 
-7 (-24 - 6) 
-42 - 14 
18, 3 
-1.5 ± 17.84 
-6 (-10.5 - 
10) 
-29 - 30 
8, 0 
-5.75 ± 
18.68 
-11 (-13.5 - 
5.5) 
-35 - 27 
8, 1 
Diastolic BP, 
mmHg 
Low -1.16 ± 
10.02 
-1 (-6 - 5) 
-32 - 26 
62, 0 
-0.06 ± 
10.16 
-1 (-7 - 5) 
-22 - 24 
101, 27 
-0.6 ± 9.89 
1 (-7 - 6) 
-25 - 17 
50, 0 
0.87 ± 10.52 
0 (-7 - 8) 
-19 - 35 
91, 28 
 High 4.2 ± 11.72 
3.5 (-4 - 
16) 
-16 - 23 
10, 0 
-4.72 ± 
10.43 
-4.5 (-13 - -
1) 
-20 - 19 
18, 3 
0.75 ± 
12.85 
1 (-6 - 4) 
-18 - 26 
8, 0 
-3.63 ± 9.88 
-1 (-13 - 3) 
-17 - 10 
8, 1 
Cholesterol, total, 
mg/dl 
Low -20.21 ± 
32.24 
-20.5 (-46 - 
3) 
-92 - 50 
62, 0 
-18.56 ± 
35.02 
-19.5 (-40 - 
-1) 
-138 - 59 
126, 2 
-14.24 ± 
27.72 
-13 (-27 - 2) 
-78 - 48 
49, 1 
-14.68 ± 
30.99 
-14 (-36 - 6) 
-93 - 64 
114, 5 
 High 15.4 ± 
40.95 
7 (-20 - 61) 
-34 - 75 
10, 0 
-10.95 ± 
37.38 
-27 (-42 - 5) 
-59 - 70 
19, 2 
14.5 ± 
38.88 
15 (-22 - 49) 
-35 - 67 
8, 0 
-11.44 ± 
70.53 
-22 (-44 - 
42) 
-126 - 100 
9, 0 
HDL, mg/dl Low -8.52 ± 
6.68 
-7 (-12 - -4) 
-26 - 4 
62, 0 
-3.29 ± 
11.92 
-4 (-8 - 1) 
-28 - 103 
126, 2 
0.88 ± 7.15 
0 (-4 - 5) 
-17 - 19 
49, 1 
6.54 ± 14.64 
7 (1 - 13) 
-114 - 50 
114, 5 
 High -6.2 ± 5.96 
-7 (-8 - 0) 
-19 - 1 
10, 0 
-2.95 ± 6.6 
-3 (-7.5 - 2) 
-14 - 10 
20, 1 
3 ± 7.15 
1.5 (-1 - 6) 
-6 - 17 
8, 0 
2.11 ± 6.47 
4 (-2 - 7) 
-9 - 10 
9, 0 
LDL, mg/dl Low -7.74 ± 
27.56 
-12.5 (-29 - 
8) 
-70 - 50 
62, 0 
-9.1 ± 
31.44 
-14 (-29.5 - 
3) 
-101 - 91 
124, 4 
-7.94 ± 
27.06 
-3 (-18 - 5) 
-70 - 59 
49, 1 
-13.63 ± 
29.57 
-14 (-33 - 5) 
-79 - 70 
113, 6 
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 High 17.4 ± 
43.51 
12 (-15 - 
57) 
-41 - 99 
10, 0 
-6.45 ± 
37.44 
-15 (-35.5 - 
21.5) 
-54 - 72 
20, 1 
12.88 ± 
36.63 
16.5 (-24.5 - 
48.5) 
-32 - 54 
8, 0 
-7.44 ± 60.6 
-24 (-52 - 
19) 
-82 - 96 
9, 0 
Triglycerides, 
mg/dl 
Low -20.21 ± 
48.86 
-8 (-40 - 
10) 
-168 - 62 
61, 1 
-24.29 ± 
61.44 
-16 (-38 - 3) 
-405 - 86 
125, 3 
-39.55 ± 
53.1 
-25 (-65 - -
10) 
-255 - 31 
49, 1 
-35.39 ± 
52.62 
-28 (-68 - -1) 
-246 - 70 
113, 6 
 High 3.3 ± 62.9 
9.5 (0 - 55) 
-147 - 71 
10, 0 
-30.75 ± 
67.7 
-23.5 (-45.5 
- -6) 
-238 - 120 
20, 1 
-6.25 ± 
66.08 
7 (-13 - 
29.5) 
-157 - 60 
8, 0 
-30.11 ± 
99.25 
-8 (-71 - 30) 
-253 - 94 
9, 0 
Glucose, mg/dl Low -12.18 ± 
22.4 
-10.5 (-24.5 
- 2.5) 
-74 - 48 
60, 2 
-16.29 ± 
42.76 
-7 (-24 - -1) 
-240 - 120 
125, 3 
-17.14 ± 
25.21 
-9 (-29 - -4) 
-80 - 55 
49, 1 
-19.49 ± 
37.78 
-9 (-25 - -3) 
-244 - 70 
116, 3 
 High -1.33 ± 
27.83 
-1 (-10 - 8) 
-53 - 36 
9, 1 
-58.9 ± 
95.6 
-12 (-70 - -
2.5) 
-274 - 5 
20, 1 
-9.29 ± 
20.81 
-5 (-16 - 1) 
-48 - 19 
7, 1 
-105.89 ± 
145.18 
-16 (-268 - -
4) 
-330 - 2 
9, 0 
Plasma Insulin, 
µIU/ml 
Low -5.97 ± 
5.29 
-6 (-9.5 - -
2.5) 
-21 - 4 
60, 2 
-8.46 ± 
6.96 
-8 (-11 - -4) 
-37 - 5 
122, 6 
-9.66 ± 6.56 
-9 (-14 - -5) 
-30 - 0 
47, 3 
-9.04 ± 6.74 
-8 (-12.5 - -
4) 
-29 - 4 
112, 7 
 High -2.2 ± 
11.82 
-2.5 (-9 - 6) 
-23 - 17 
10, 0 
-2.75 ± 
7.66 
-3 (-7.5 - 
2.5) 
-17 - 12 
20, 1 
-1 ± 10.69 
1 (-6 - 5) 
-21 - 13 
8, 0 
-0.63 ± 
11.02 
-0.5 (-9 - 
8.5) 
-17 - 14 
8, 1 
HbA1C, % Low -0.59 ± 
0.81 
-0.3 (-0.8 - 
-0.1) 
-4.7 - 0.3 
62, 0 
-0.7 ± 1.08 
-0.4 (-0.8 - -
0.2) 
-8 - 0.4 
121, 7 
-0.69 ± 0.68 
-0.5 (-0.9 - -
0.3) 
-2.7 - 0.2 
47, 3 
-0.71 ± 0.97 
-0.5 (-0.9 - -
0.2) 
-7.3 - 0.8 
110, 9 
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 High -0.58 ± 
0.47 
-0.45 (-0.8 
- -0.3) 
-1.5 - 0.2 
10, 0 
-1.22 ± 
2.32 
-0.2 (-1.1 - -
0.05) 
-8.7 - 0.1 
20, 1 
-0.87 ± 1.21 
-0.3 (-2.2 - 
0) 
-2.9 - 0.2 
7, 1 
-3.13 ± 3.02 
-2.75 (-4.6 - 
-0.3) 
-8.2 - -0.2 
6, 3 
HsCRP, mg/dl Low -3.74 ± 
12.7 
-1.35 (-2.9 
- -0.1) 
-72.8 - 17.5 
42, 20 
-3.88 ± 
8.87 
-3.25 (-8.8 - 
-0.7) 
-21.6 - 43.9 
102, 26 
-5.97 ± 6.45 
-3.55 (-7.8 - 
-2.15) 
-24.8 - 1.8 
32, 18 
-6.75 ± 8.02 
-5.25 (-12.1 
- -2.05) 
-37.8 - 21.8 
88, 31 
 High -1.31 ± 
5.22 
-0.6 (-4.4 - 
0.6) 
-9.3 - 7.8 
7, 3 
-2.1 ± 8.68 
-2.95 (-7.2 - 
-1.1) 
-13 - 22.2 
18, 3 
-2.6 ± 2.98 
-2.1 (-5.8 - 
0.1) 
-5.8 - 0.1 
3, 5 
-5.77 ± 3.46 
-5.85 (-7 - -
4.6) 
-10.9 - -0.4 
6, 3 
CRP, mg/dl Low -0.58 ± 
0.95 
-0.6 (-1.3 - 
0.2) 
-2.4 - 0.7 
11, 51 
-1.95 ± 
2.69 
-1 (-3.55 - -
0.35) 
-5.9 - 0.1 
4, 124 
-0.9 ± 0.87 
-0.5 (-1.4 - -
0.4) 
-2.2 - -0.4 
4, 46 
-0.5 ± 0.14 
-0.4 (-0.6 - -
0.4) 
-0.7 - -0.4 
5, 114 
 High 0.05 ± 1.34 
0.05 (-0.9 - 
1) 
-0.9 - 1 
2, 8 
-1.05 ± 
1.48 
-1.05 (-2.1 - 
0) 
-2.1 - 0 
2, 19 
-0.05 ± 0.35 
-0.05 (-0.3 - 
0.2) 
-0.3 - 0.2 
2, 6 
. ± . 
. (. - .) 
. - . 
0, 9 
Creatinine, mg/dl Low -0.04 ± 0.1 
-0.03 (-0.1 
- 0.04) 
-0.24 - 0.19 
58, 4 
-0.11 ± 
0.15 
-0.08 (-0.16 
- -0.03) 
-1.18 - 0.21 
124, 4 
-0.07 ± 0.12 
-0.08 (-0.17 
- 0.02) 
-0.3 - 0.11 
49, 1 
-0.06 ± 0.12 
-0.05 (-0.13 
- 0) 
-0.46 - 0.33 
110, 9 
 High -0.03 ± 
0.12 
-0.03 (-0.07 
- 0.02) 
-0.2 - 0.21 
10, 0 
-0.06 ± 
0.18 
-0.02 (-0.09 
- 0.01) 
-0.57 - 0.22 
20, 1 
-0.07 ± 0.1 
-0.07 (-0.15 
- 0.01) 
-0.2 - 0.09 
8, 0 
-0.11 ± 0.16 
-0.02 (-0.19 
- 0) 
-0.45 - 0 
8, 1 
Urine Creatinine, 
mg/dl 
Low 1574.09 ± 
1470.05 
1773 (476 - 
2502) 
-3080 - 
4391 
59, 3 
614.29 ± 
1316.97 
699 (-278 - 
1552) 
-3044 - 
3986 
59, 69 
351.41 ± 
1352.53 
272 (-457 - 
855) 
-2721 - 
3959 
47, 3 
-171.59 ± 
1046.89 
-51.9 (-831 - 
360) 
-3019.1 - 
1982 
59, 60 
 76 
 High 886.25 ± 
1391.06 
537 (231.5 
- 847) 
-328 - 4187 
8, 2 
747.48 ± 
1209.27 
596.5 (-8.9 
- 1807.5) 
-1652 - 
2392 
12, 9 
70.83 ± 
1823.7 
542 (-943 - 
1120) 
-3254.2 - 
2575 
7, 1 
-511.7 ± 
1642.89 
-511.7 (-
1673.4 - 
650) 
-1673.4 - 
650 
2, 7 
BMI, kg/m2 Low -4.81 ± 
1.54 
-4.8 (-5.78 
- -3.79) 
-8.75 - -
1.87 
62, 0 
-7.99 ± 
2.16 
-7.96 (-9.37 
- -6.63) 
-14.72 - 
0.31 
128, 0 
-11.72 ± 
3.72 
-12.47 (-
14.35 - -
9.32) 
-18.98 - -1.1 
49, 1 
-13.76 ± 
5.24 
-13.18 (-
16.21 - -
10.34) 
-32.37 - -
0.28 
117, 2 
 High -4.49 ± 
1.37 
-4.11 (-5.39 
- -3.54) 
-7.34 - -
2.83 
10, 0 
-6.56 ± 3.5 
-6.93 (-8.65 
- -5.08) 
-11.87 - 
1.63 
21, 0 
-8.04 ± 7.23 
-8.27 (-
12.79 - -
2.15) 
-19.5 - 1.58 
8, 0 
-11.07 ± 
6.03 
-10.23 (-
10.76 - -
7.66) 
-21.73 - -
3.36 
9, 0 
HOMA-IR Low -1.85 ± 
1.65 
-1.71 (-2.62 
- -0.58) 
-7.33 - 1.11 
58, 4 
-2.74 ± 
3.09 
-1.85 (-3.51 
- -1.05) 
-16.63 - 
1.97 
119, 9 
-2.94 ± 2.27 
-2.42 (-4.23 
- -1.15) 
-9.04 - -0.1 
46, 4 
-2.8 ± 2.49 
-2.07 (-3.88 
- -1.13) 
-12.03 - 1.2 
109, 10 
 High -0.24 ± 
3.43 
-0.79 (-1.54 
- 1.3) 
-4.7 - 6.48 
9, 1 
-2.59 ± 3.6 
-1.96 (-4.59 
- 0.02) 
-10.81 - 
2.98 
19, 2 
0.07 ± 2.74 
0.6 (0.05 - 
0.86) 
-5.61 - 3.43 
7, 1 
-2.74 ± 4.55 
-1.85 (-5.36 
- 0.45) 
-11.04 - 2.66 
8, 1 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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Table A.5. Descriptive Statistics Stratified by Baseline Plasma Insulin Level for 
FMD (%), by Visit 
 
Insulin Status Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
1 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12. mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Low Baseline 
Insulin 
10.28 ± 5.18 
9.81 (6.39 - 
13.6) 
-3.29 - 25.72 
162, 6 
9.04 ± 4.74 
7.75 (5.14 - 
12.24) 
0.43 - 20.8 
60, 2 
10.5 ± 5.02 
9.98 (7.09 - 
12.97) 
1.61 - 30.22 
115, 13 
10.43 ± 4.83 
10.36 (7.37 - 
11.94) 
2.59 - 23.85 
49, 1 
10.85 ± 5.03 
10.74 (7.01 - 
14.69) 
1.52 - 25.44 
101, 18 
High 
Baseline 
Insulin 
9.16 ± 5.43 
9.07 (4.66 - 
12.91) 
-2.65 - 24.2 
162, 6 
9.45 ± 5.96 
10.06 (4.18 - 
14.22) 
1.21 - 18.69 
10, 0 
10.88 ± 4.85 
10.96 (7.85 - 
14.5) 
2.54 - 19.24 
16, 5 
13.9 ± 5.29 
15.63 (9.41 - 
18.13) 
5.25 - 19.65 
8, 0 
9.21 ± 3.65 
7.89 (7.28 - 
10.53) 
5.49 - 16.77 
8, 1 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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Table A.6. Descriptive Statistics Stratified by Baseline Plasma Insulin Level for 
NMD (%), by Visit 
 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
1 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Low 
Baseline 
Insulin 
15.39 ± 5.52 
14.8 (12.19 - 
20.12) 
4.69 - 26.3 
50, 118 
15.41 ± 6.39 
14.7 (11.53 - 
19.4) 
6.54 - 26.7 
17, 45 
17.11 ± 7.58 
15.24 (11.47 
- 22.75) 
4.12 - 35.39 
25, 103 
16.39 ± 4.84 
15.74 (13.45 
- 19.9) 
6.86 - 25.24 
15, 35 
17.32 ± 6.05 
18.61 (11.83 
- 21.78) 
5.3 - 27.49 
28, 91 
High 
Baseline 
Insulin 
14.05 ± 7.01 
12.69 (9.46 - 
18.45) 
3.83 - 36.82 
40, 128 
14.23 ± 3.08 
15.53 (12.57 
- 15.9) 
9.64 - 16.23 
4, 6 
22.08 ± 
11.45 
20.64 (11.42 
- 34.18) 
11.42 - 34.18 
3, 18 
15.12 ± 11.4 
12.05 (5.56 - 
27.73) 
5.56 - 27.73 
3, 5 
11.11 ± . 
11.11 (11.11 
- 11.11) 
11.11 - 11.11 
1, 8 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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Table A.7. Descriptive Statistics Stratified by Baseline Plasma Insulin Level for ∆ 
Hyperemic Flow (%), by Visit 
Insulin 
Status 
Baseline 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
1 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. 
Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Low 
Baseline 
Insulin 
856.69 ± 
418.69 
848.26 
(553.79 - 
1076.11) 
-4.61 - 
2146.67 
140, 28 
922.63 ± 
406.04 
852.38 
(633.64 - 
1200.05) 
241.77 - 
2052.57 
49, 13 
934.63 ± 
391.82 
908.77 
(653.08 - 
1179.96) 
-3.87 - 
2099.15 
103, 25 
912.9 ± 
453.17 
896.52 
(518.58 - 
1240.39) 
162.58 - 
2147.48 
38, 12 
951.21 ± 
409.75 
947.96 
(636.14 - 
1199.1) 
162.89 - 
2408.5 
90, 29 
High 
Baseline 
Insulin 
658.08 ± 
366.93 
571.32 
(389.19 - 
853.2) 
-99.13 - 
2007.87 
130, 38 
848.05 ± 
676.36 
672.39 (409.2 
- 861.11) 
275.88 - 
2310.85 
7, 3 
645.84 ± 
324.42 
584.19 
(395.57 - 
930.84) 
12.13 - 
1091.55 
14, 7 
588.02 ± 
320.07 
679.94 
(315.02 - 
724.86) 
218.31 - 1002 
5, 3 
848.23 ± 
375.24 
829.45 
(767.66 - 
881.54) 
302.39 - 
1478.85 
6, 3 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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Table A.8. Differences from Baseline Stratified by Baseline Plasma Insulin Level 
for FMD (%), by Follow-up Visit 
Insulin Status 1 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Low Baseline 
Insulin 
0.43 ± 5.55 
1.2 (-2.45 - 
3.77) 
-13.58 - 11.85 
59, 3 
1.65 ± 5.09 
1.54 (-1.14 - 
5.12) 
-16.25 - 14.64 
114, 14 
1.36 ± 5.74 
1.01 (-1.93 - 
4.36) 
-10.43 - 14.29 
48, 2 
1.24 ± 5.55 
1.13 (-2.27 - 
3.93) 
-23.47 - 17.14 
95, 24 
High Baseline 
Insulin 
0.84 ± 4.65 
2.19 (-4.04 - 
2.86) 
-5.81 - 8.04 
10, 0 
0.73 ± 3.85 
-0.66 (-1.7 - 
2.62) 
-4.98 - 9.56 
16, 5 
4.72 ± 4.76 
3.02 (1.37 - 
7.98) 
-0.5 - 13.49 
8, 0 
3.39 ± 6 
2.62 (-0.8 - 
5.42) 
-3 - 15.62 
8, 1 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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Table A.9. Differences from Baseline Stratified by Baseline Plasma Insulin Level 
for NMD (%), by Follow-up Visit 
 
Insulin Status 1 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Low Baseline 
Insulin 
0.96 ± 4.12 
2.3 (-2.65 - 4.16) 
-5.73 - 7.35 
15, 47 
2.3 ± 5.54 
2.88 (-0.72 - 
4.45) 
-8 - 13.39 
21, 107 
4.13 ± 7.54 
2.59 (-2.61 - 
9.02) 
-8 - 16.32 
11, 39 
4.59 ± 6.43 
4.11 (0.82 - 
8.59) 
-5.98 - 18.1 
21, 98 
High Baseline 
Insulin 
-5.99 ± . 
-5.99 (-5.99 - -
5.99) 
-5.99 - -5.99 
1, 9 
4.78 ± 6.18 
5.86 (-1.87 - 
10.35) 
-1.87 - 10.35 
3, 18 
1.56 ± 2.07 
0.77 (0 - 3.91) 
0 - 3.91 
3, 5 
0.55 ± . 
0.55 (0.55 - 
0.55) 
0.55 - 0.55 
1, 8 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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Table A.10. Differences from Baseline Stratified by Baseline Plasma Insulin Level 
for ∆ Hyperemic Flow (%), by Follow-up Visit 
 
Insulin Status 1 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
3 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
6 mo. Follow-up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
12 mo. Follow-
up 
Mean 
± SD 
Median 
(IQR) 
Range 
N, N Missing 
Low Baseline 
Insulin 
96.74 ± 471.65 
131.17 (-229.64 
- 403.3) 
-1317.98 - 
1108.43 
45, 17 
222.06 ± 483.22 
218.92 (-41.86 - 
470.07) 
-1558.28 - 
1622.93 
100, 28 
211.5 ± 567.43 
190.7 (-217.65 - 
519.11) 
-913.37 - 
1567.18 
36, 14 
251.94 ± 520.82 
268.44 (-110.85 - 
524.82) 
-1039.33 - 
1456.1 
78, 41 
High Baseline 
Insulin 
-1.92 ± 874.16 
57.91 (-13.82 - 
537) 
-1775.52 - 
1063.27 
7, 3 
-103.76 ± 362.8 
-86.26 (-500.35 - 
137.24) 
-543.01 - 626.1 
11, 10 
-116.69 ± 526.14 
-170.88 (-613.63 
- 434.45) 
-613.63 - 434.45 
3, 5 
298.91 ± 493.52 
220.64 (-58.79 - 
480.57) 
-233.05 - 
1163.44 
6, 3 
Low baseline plasma insulin is considered ≤ 13.5 µIU/ml and high baseline plasma 
insulin is considered > 13.5 µIU/ml. IQR is interquartile range, N is the number of 
patients included in analysis for the parameter, and N Missing is the number of patients 
from the total study population not included in analysis for the parameter. 
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